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ABSTRACT 
 
 The molecular mechanisms underlying susceptibility to severe respiratory 
syncytial virus (RSV) infection remain poorly understood. Herein, we report on the role of 
osteopontin (OPN) in regulation of RSV infection in human epithelial cells and how 
interleukin-1 beta (IL-1β), a cytokine secreted soon after RSV infection, when persistently 
expressed can induce OPN expression leading to increased viral infection. We first 
compared OPN expression in two human epithelial cell lines: HEK-293 and HEp-2. In 
contrast to HEp-2, HEK-293 expresses low levels of pro-caspase-1 resulting in decreased 
IL-1β expression in response to RSV infection. We found a correlation between low IL-1β 
levels and a delay in induction of OPN expression in RSV-infected HEK-293 cells 
compared to HEp-2. This phenomenon could partially explain the high susceptibility of 
HEp-2 cells to RSV infection versus the moderate susceptibility of HEK-293 cells.  Also, 
HEK-293 cells expressing low levels of pro-caspase-1 exhibit decreased IL-1β expression 
and delayed OPN expression in response to RSV infection. HEK-293 cells incubated with 
human rIL-1β showed a dose-dependent increase in OPN expression upon RSV 
infection. Also, incubation with rOPN increased RSV viral load. Moreover, HEp-2 cells or 
mice infected with a mucogenic RSV strain RSV-L19F showed elevated levels of OPN in 
contrast to mice infected with the laboratory RSV strain rA2. This correlated with elevated 
levels of OPN following infection with RSV-L19F compared to rA2. Together, these results 
demonstrate that increased OPN expression is regulated in part by IL-1β, and the 
v 
interplay between IL-1β and OPN signaling has a pivotal role in the spread of RSV 
infection.  
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INTRODUCTION 
 
     Objective 
The objective of this dissertation is to explore the role of OPN in the pathogenesis 
and inflammatory response to RSV and to evaluate OPN as a regulator of severe RSV 
infection.    
 
           Motivation 
The motivation for this work is to elucidate the role of OPN in RSV infection and its 
contribution to the outcome of the disease. The work presented herein will reveal the 
mechanism by which OPN contributes to RSV infection. Our approach allows us to 
evaluate the role of IL-1β in the regulation of OPN expression during RSV infection, as 
well as OPN’s role during the inflammatory response thus influencing the onset of 
infection and its severity.  
 
           Scope  
The scope of this project is to have a better understanding of the inflammatory 
response to RSV infection.  Severe RSV infection is associated with increased viral 
replication and uncontrolled inflammation. This uncontrolled inflammation is a major 
contributor to the disease pathology presented by patients with severe RSV infection. In 
the future, these findings would help to develop new drug targets for treatments and/or 
 2 
prophylaxis of RSV infection because they may lead to development of pharmacological 
strategies to regulate  Il-1β and OPN expression during the infection, which could 
minimize the inflammatory response  and control the replication of the virus. 
 
           Overview 
Chapter 1 introduces background information on RSV infection, the susceptible 
population and available treatments, as well as the biology of the virus and molecular 
mechanisms developed by the virus to disrupt the immune response. Chapter 2 
introduces a detailed description of all molecular biology techniques used and 
experimental designs. Chapters 3-5 will cover three areas: 1) how OPN expression is 
affected by RSV infection and disease; 2) the role of RSV-induced IL-1β expression 
during up-regulation of OPN; and 3) the correlation between OPN and severe RSV 
infection. Each chapter will include relevant background information and explanation of 
the results and discussion. Chapter 6 will summarize all the findings and contributions of 
this study. A correlation of all the results is included to assist readers in making quick 
approximations of the data presented and to demonstrate the usefulness of the model.  
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CHAPTER 1 
RESPIRATORY SYNCYTIAL VIRUS - LITERATURE REVIEW 
 
1.1     RSV Clinical Relevance  
Respiratory syncytial virus (RSV) infection is one of the first pathogens 
encountered by the infant immune system. It is estimated that RSV infects most people 
by two years of age, and it may re-infect individuals throughout life since infection does 
not lead to persistent or long-lasting immunity [1-3]. Severe RSV infection is common in 
infants and individuals above 65 years of age because their immune system is either 
immature or gradually diminished due to age advancement; thus their capacity to 
efficiently respond to an infection is impaired [4, 5]. The global incidence of RSV infection 
is estimated to be 34 million cases per year in children younger than five years, and 
results in more than 90,000 hospitalizations a year in the United States [6-8]; the overall 
incidence of RSV disease in elderly adults in the U.S. is ~3-4% with an estimated 10,000 
deaths per year [5, 9, 10]. Most primary infections are identified by cold-like symptoms, 
coughing, fever, shortness of breath, runny nose and lethargy; however, some RSV 
infections will lead to severe obstruction of airways, alveolar epithelium damage, and 
edema resulting in pneumonia and/or bronchiolitis that may require hospitalization. Death 
may ensue if complications persist [10-12]. Despite the significant impact RSV has on 
current health care systems and decades of intense research in the field, no vaccine or 
effective treatment is available and the infection is typically managed solely by supportive 
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care. Currently, Palivizumab is the only prophylactic drug approved by the Food and Drug 
Administration (FDA) for use in the United States. It is based on neutralizing antibodies 
targeting the fusion glycoprotein of RSV; however, Palivizumab is administered by 
multiple intramuscular (IM) injections before and during the RSV season which makes it 
an expensive prophylactic treatment only approved for high-risk infants [13-15].  
Remarkably, viral infections trigger 80-85% of asthma exacerbations in children, 
and around 45% in adults [16-18]. Moreover, viral infections stimulate immune cells to 
produce inflammatory cytokines, which increase mucus production in the airways 
resulting in airway obstruction. Viral stimulation of pro-inflammatory cytokines also causes 
airway hyperresponsiveness that has been associated with irreversible pulmonary 
damage in children with cystic fibrosis [19-22]. RSV infection is associated with wheezing 
and asthma exacerbations [16, 20, 23, 24]. The nature of this association is not fully 
understood, but the fact that RSV infection induces a Th2-like cytokine profile may explain 
the risk for the development of asthma after the infection [20, 25-27].  
 
 
1.2      Biology and Structure  
RSV is a negative-sense, non-segmented, single-stranded RNA virus with a 15.2 
kb genome that belongs to Paramyxoviridae family, order Mononegavirales [28, 29]. The 
negative-sense genome contains 10 viral genes that encode 11 viral proteins. Each gene 
is transcribed into a messenger RNA (mRNA) and codes for a single viral protein, except 
the M2 mRNA which is known to have two overlapping open reading frames that lead to 
the expression of two different proteins M2-1 and M2-2 [29, 30]. Briefly, once RSV enters 
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the host airway epithelial cells via direct fusion of the viral envelope on lipid raft domains 
within the plasma membrane [31]. The RSV-F and RSV-G proteins mediate the fusion 
and attachment process by interacting with different cellular receptors such as CX3 
chemokine receptor 1 (CX3CR1), toll like receptor-4 (TLR-4), annexin II, nucleolin, CD44 
receptor, among others [32-34]. Although the exact function of the previously mentioned 
receptors remains inconclusive. It is known that the activation of cell signaling pathways 
contribute to successful entry of the virus and subsequent production of viral filaments 
[33]. Following the fusion event comes RSV internalization process that leads to release 
of the genomic material and the RSV-L RNA dependent RNA polymerase (RdRp) to the 
cytoplasm where transcription and replication take place; hence the polymerase 
generates polyadenylated and capped mRNAs that are translated to non-structural and 
structural proteins [35, 36]. Finally, the anti-genome is the template used by the RdRp to 
produce adequate genomic negative-sense RNA which is encapsidated with the viral 
nucleoprotein and assembled with all the other viral proteins before the virus is released 
from the infected cell. The budding process allows progeny viral particles to retain the 
host cell plasma membrane as their envelope (Fig. 1). 
RSV genes are transcribed in the following order. First are the non-structural 
proteins 1 and 2 (NS1/NS2) which, although not found in the virion, are accessory proteins 
present in the infected cells that have been involved in disruption of the antiviral immune 
response by inhibiting the type I interferon (IFN) signaling pathway at different points, thus 
facilitating viral replication [37-39]. Those proteins are followed by the nucleocapsid 
protein (N) which is critical for viral transcriptional activity and encapsidates both the 
genomic RNA and the antigenome. The phosphoprotein (P) is an important co-factor in 
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RNA synthesis that gets phosphorylated in order to create a functional polymerase 
complex [40, 41]. Likewise, the matrix protein (M) is essential during viral assembly, 
release, and production of infectious viral particles [42]. The next three glycoproteins are 
heavily glycosylated proteins found anchored to the surface of the viral envelope: a small 
hydrophobic protein (SH) whose function is not fully elucidated but is suggested to play 
an immumodulatory role [43]; the attachment glycoprotein (G) which, while not required 
for in vitro infection, seems important for optimal in vivo  viral growth and facilitates viral 
adsorption to the host cells allowing the attachment of the virus to the cell [44]; and the 
fusion protein (F) which mediates the penetration of the virus to the cell by allowing the 
fusion of the viral envelope and the host cell membrane.  F protein also allows the 
passage of RSV from cell to cell and the fusion of neighboring infected cell plasma 
membranes producing giant multinucleated  cells known as syncytia; the formation of 
which is characteristic of RSV infection [45, 46]. M2-1 is a transcription elongation factor 
that allows transcription through the intergenic regions and increases the expression of 
genes found at the distal region; M2-2 regulates viral transcription by changing the 
polymerase complex (N, P and L proteins) from a transcriptional to a replicative mode 
which is critical for a proper propagation of the virus [30, 47, 48]. Lastly, the large protein 
(L) is the major subunit of the RNA-dependent RNA polymerase [49]. 
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Figure 1. RSV replication cycle. RSV-F and RSV-G glycoproteins mediate fusion and 
attachment of the virus to the airway epithelial cell. The virus enters the cell and releases 
its encapsidated genomic material and the RSV RNA-dependent RNA polymerase 
(RdRp) into the cytoplasm where RNA replication takes place and the RdRp enzyme uses 
the genome as a template to generate mRNA that codify the 11 viral proteins. Lastly, the 
genomic RNA is encapsidated and assembled with the other viral proteins to produce 
progeny viral particles that bud from the host cells while taking the plasma membrane as 
their envelope. 
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1.3      Antigenic Subgroups 
Although there exists only one serotype of RSV, it consists of two major antigenic 
subgroups (A and B). These subgroups have been identified through gene sequencing 
and cross-neutralization reactions with monoclonal antibodies [50]. Although disparities 
have been reported in all the structural proteins, the major differences between subgroups 
A and B are found in the G and F surface proteins, with respectively 53% and 90% amino 
acid sequence identity [50-52]. The two strains alternate during yearly epidemics thus 
leading to their re-circulation, which may account for frequent re-infections during the 
same or next RSV season [53]. Additionally, some studies have suggested that RSV A is 
more prevalent and associated with greater severity of disease compared to RSV B [49, 
51, 54]. On the contrary, others found that strain differences do not play a significant role 
in the onset and severity of RSV disease [49, 55].  
 
 
1.4      Immune Response to RSV  
Host innate and cellular immunity mediates the clinical outcome and resolution of 
microbial infections, but it also controls the propensity for severe disease and re-infection 
[56]. Airway epithelial cells, immune cells and tissues express pattern-recognition 
receptors (PRRs) capable of recognizing pathogen-associated molecular patterns 
(PAMPS), thus activating the innate immune response, causing the release of pro-
inflammatory cytokines leading to pathogen clearance, but also mediating disease 
pathology [57]. During viral infections the cascade of signaling events is initiated mainly 
by retinoic acid-inducible gene (RIG)-like receptors (RLRs), which include RIG-I, MDA5 
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and LGP2; toll-like receptors (TLRs); and (NOD)-like receptors (NLRs) that recognize viral 
genomic material such as single-stranded RNA (ssRNA), double stranded RNA (dsRNA) 
and DNA [57, 58]. Upon RSV infection, ssRNA and dsRNA are detected in the endosomal 
compartment by TLR-3 and TLR-7, and in the cytosol by MDA5, RIG-I and NLR receptors 
[59]. The stimulation of these signaling pathways leads to activation of transcription 
factors IRF-3, IRF-7 and NF-kB that result in production of type I interferon (IFNα,β) and 
pro-inflammatory cytokines [58].  
The IFN response pathway is considered the first line of defense against viral 
infection; hence a proper production of type I IFN (IFNα and IFNβ) is essential during the 
innate immune response to control the infection [60].  IFNα/β are secreted and bind to 
cell surface receptors (IFNAR) that induce the transcription of interferon-stimulated genes 
(ISG) to elicit antiviral, antiproliferative and immunomodulatory activities [61]. 
Interestingly, RSV has the capability to subvert the host immune response, particularly 
the IFN signaling pathway. Expression of the nonstructural RSV proteins, NS1 and NS2, 
has been associated with poor induction of the type I IFN response. Infections with RSV 
lacking either the NS1 or NS2 gene have shown enhanced IFN induction and reduced 
replication efficiency [38, 62]. NS1 and NS2 cause proteosomal degradation of host 
STAT2, and likewise a decrease in NF-κB activation [63, 64]. Particularly, NS1 protein 
binds to the mitochondrial antiviral signal protein (MAVS) and NS2 interacts with RIG-I 
but not MAVS [38, 63]. Therefore, evidence demonstrates that the RSV NS1 and NS2 
proteins together antagonize IFN induction [38]. 
In addition to type I IFN production, epithelial cells respond to RSV infection by 
expressing inflammatory cytokines resulting in tissue remodeling, increased mucus 
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production, and airway obstruction that worsens the symptoms and results in 
exacerbation of allergy and asthma. Other cytokines produced during RSV infection 
include interleukin-6 (IL-6), IL-8, IL-1β, IL-10, IL-13, TNFα, RANTES (CXCL5), IL-17, 
macrophage inflammatory protein 1α (MIP-1α), GM-CSF, IL-1α, IL-25, and IL-33 [62, 65]. 
In an effort to elucidate the genes that are associated with RSV pathology and age-related 
weakening of the immune system our lab previously analyzed 84 different antiviral genes 
and established the association between those genes, age and infection. Five genes out 
of 84 were associated with both advanced age and RSV infection, RIG-I, IFNAR1, TLR-
8, IL-1β, and Osteopontin (OPN) [4]. Our previous results showed that aged mice express 
pro-inflammatory cytokines even prior to infection which may explain the susceptibility of 
these animals to a severe form of disease caused by RSV infection and their difficulty to 
clear the infection efficiently compared to the young group [4]. 
As with other viral infections, RSV infection triggers recruitment and activation of 
immune cells: natural killer cells (NK), macrophages, monocytes, granulocytes, T 
lymphocytes and dendritic cells (DC) [66]. Although these cells can induce a direct 
effector immune response that controls the local infection, they also serve as a bridge to 
initiate a proper acquired immune response [67]. In mouse models of RSV infection, 
neutralizing antibodies control the spread of the infection from upper to lower respiratory 
tract [68]. In humans, RSV induces Immunoglobulin A (IgA) secretion in the upper 
respiratory tract which, although a short-lived immune response, controls the infection 
and its progression to the lower respiratory tract [69]. Although passive immunity is 
transitory during RSV infection, neutralizing antibodies against RSV have been reported 
in serum from full term newborns; thus primary infections of infants usually does not lead 
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to a severe form of infection since maternal antibodies protect them of a lower tract 
respiratory infection [70-72]. Later in life neutralizing antibodies are developed during 
natural infections, with higher titers in adults compared to infants infected, which could be 
explained by the latter group’s immature immune system [73].  
Unfortunately, RSV induces a short immune response that does not protect from 
future infections. Additionally, the uncontrolled inflammation increases the severity of the 
disease. Further studies are required to establish the role of the inflammatory response 
and its association with disease progression so that effective treatments can be 
developed. 
 
 
1.5      Current Treatments  
RSV was first discovered in 1956 in a laboratory chimpanzee with respiratory tract 
infection. It was soon established as a leading viral pathogen able to cause serious 
respiratory infection in the infant population. Despite years of intense research and 
several attempts to identify new and effective treatments to minimize clinical 
hospitalizations and complications due to RSV infection, there is no vaccine available for 
RSV infection and the standard treatment is basic supportive care with limited 
pharmacologic treatment in extreme cases [74]. 
Ribavirin is the only antiviral drug approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of RSV. It acts by inhibiting the transcription and 
replication of a variety of viruses, thus it is not exclusively used to treat RSV infection [75, 
76]. In fact, ribavirin is not as effective for RSV as it is for other viruses and it is only used 
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as a treatment of severely ill children and immunocompromised patients infected with 
RSV in order to reduce the disease progression from upper to lower respiratory tract 
infection thus reducing mortality [77, 78]. 
Another well-known approach is the administration of a prophylactic treatment 
consisting of a humanized monoclonal antibody against the F protein of RSV 
(Palivizumab) made of 95% human and 5% mouse antibody sequence, thus helping to 
reduce pulmonary viral replication [79, 80]. Palivizumab is currently administered to 
children at high risk of RSV disease, for instance, premature infants, infants born with 
congenital heart disease, neuromuscular disorders, and immunocompromised children 
among others. It is administered monthly during the RSV season by intramuscular route 
in a dose of 15 mg per kg; a maximum of 5 consecutive doses has been recommended 
by the American academy of pediatrics to ensure immune protection; moreover a 55% 
reduction in hospitalization by RSV has been reported and attributed to treatment with 
palivizumab [80, 81]. Despite the benefits of a prophylactic treatment in infants at risk of 
severe RSV disease, the use of palivizumab is limited due to the high cost of the treatment 
[80].  
RSV vaccine development has been challenging and remains a priority since RSV 
infection does not lead to sustained or long lasting immunity. The first unsuccessful 
attempt to develop an RSV vaccine consisted of a formalin-inactivated vaccine; recipients 
had an increased rate of infection and hospitalizations due to the infection compared to 
the control group; additionally, the death of two participants of the clinical trial was 
attributed to the vaccine [82]. Further studies proposed that the formalin-inactivated virus 
was not able to stimulate PRRs; consequently, it did not trigger an appropriate innate 
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immune response but the activation of other arms of the immune system that led to strong 
priming of T cells towards a Th2 lineage, resulting in the increased expression of Il-4 and 
Il-5 both associated to enhanced inflammatory infiltrate and pulmonary eosinophilia [83, 
84]. Although inducing a robust immune response is the aim of vaccination, formalin-
inactivated RSV vaccine is a good example of how vaccines can be harmful when 
uncontrolled stimulation of the immune response is induced [85]. 
 
 
1.6     Concluding Remarks 
Despite more than six decades of research aiming to develop effective treatments 
and vaccine candidates for RSV infection, the treatments available remain supportive and 
there is still a lack of cost-effective prophylactic treatment or effective vaccine candidates. 
Thus, severe RSV infections remain a constant risk for infant, elderly and individuals who 
are immunocompromised. A proper understanding of the immune response to the 
infection is essential since it is known that severe RSV infection is not only driven by an 
increase in viral replication but also by an imbalanced immune response that leads to 
exaggerated inflammation [86].  
 
 
1.7     References 
1. Piedimonte, G. and M.K. Perez, Alternative mechanisms for respiratory syncytial 
virus (RSV) infection and persistence: could RSV be transmitted through the 
placenta and persist into developing fetal lungs? Current Opinion in Pharmacology, 
2014. 16(0): p. 82-88. 
14 
 
2. Hall, C.B., et al., Immunity to and Frequency of Reinfection with Respiratory 
Syncytial Virus. Journal of Infectious Diseases, 1991. 163(4): p. 693-698. 
3. Scott, P.D., et al., Molecular Analysis of Respiratory Syncytial Virus Reinfections 
in Infants from Coastal Kenya. Journal of Infectious Diseases, 2006. 193(1): p. 59-
67. 
4. Wong, T.M., et al., Respiratory Syncytial Virus (RSV) Infection in Elderly Mice 
Results in Altered Antiviral Gene Expression and Enhanced Pathology. PLOS 
ONE, 2014. 9(2): p. e88764. 
5. Cherukuri, A., et al., Adults 65 years old and older have reduced numbers of 
functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine 
Immunol, 2013. 20(2): p. 239-47. 
6. Zomer-Kooijker, K., et al., Increased Risk of Wheeze and Decreased Lung 
Function after Respiratory Syncytial Virus Infection. PLoS ONE, 2014. 9(1): p. 
e87162. 
7. Nair, H., et al., Global burden of acute lower respiratory infections due to 
respiratory syncytial virus in young children: a systematic review and meta-
analysis. The Lancet, 2010. 375(9725): p. 1545-1555. 
8. Gutfraind, A., A.P. Galvani, and L. Meyers, Efficacy and optimization of 
palivizumab injection regimens against respiratory syncytial virus infection. JAMA 
Pediatrics, 2015. 169(4): p. 341-348. 
9. Falsey, A.R., et al., Acute Respiratory Tract Infection in Daycare Centers for Older 
Persons. Journal of the American Geriatrics Society, 1995. 43(1): p. 30-36. 
10. Thompson, W.W., et al., Mortality associated with influenza and respiratory 
syncytial virus in the united states. JAMA, 2003. 289(2): p. 179-186. 
11. Fleming, D.M., R.S. Pannell, and K.W. Cross, Mortality in children from influenza 
and respiratory syncytial virus. Journal of Epidemiology and Community Health, 
2005. 59(7): p. 586-590. 
12. Bera, M.M., et al., Th17 Cytokines Are Critical for Respiratory Syncytial Virus-
Associated Airway Hyperreponsiveness through Regulation by Complement C3a 
and Tachykinins. The Journal of Immunology, 2011. 187(8): p. 4245-4255. 
13. Group, T.I.-R.S., Palivizumab, a Humanized Respiratory Syncytial Virus 
Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus 
Infection in High-risk Infants. Pediatrics, 1998. 102(3): p. 531-537. 
14. Hu, J. and J. Robinson, Treatment of respiratory syncytial virus with palivizumab: 
a systematic review. World Journal of Pediatrics, 2010. 6(4): p. 296-300. 
15 
 
15. Sáez-Llorens, X., et al., Safety and Pharmacokinetics of Palivizumab Therapy in 
Children Hospitalized with Respiratory Syncytial Virus Infection. The Pediatric 
Infectious Disease Journal, 2004. 23(8): p. 707-712. 
16. Wang, J., et al., BuShenYiQi Formula strengthens Th1 response and suppresses 
Th2-Th17 responses in RSV-induced asthma exacerbated mice. Journal of 
Ethnopharmacology, 2014. 154(1): p. 131-147. 
17. Johnston, S.L., et al., Community study of role of viral infections in exacerbations 
of asthma in 9-11 year old children. BMJ, 1995. 310(6989): p. 1225-1229. 
18. Carroll, K.N., et al., Respiratory syncytial virus immunoprophylaxis in high-risk 
infants and development of childhood asthma. Journal of Allergy and Clinical 
Immunology, 2017. 139(1): p. 66-71.e3. 
19. Midulla, F., et al., Recurrent wheezing 36 months after bronchiolitis is associated 
with rhinovirus infections and blood eosinophilia. Acta Paediatrica, 2014: p. n/a-
n/a. 
20. Matsuse, H., et al., Recurrent Respiratory Syncytial Virus Infections in Allergen-
Sensitized Mice Lead to Persistent Airway Inflammation and 
Hyperresponsiveness. The Journal of Immunology, 2000. 164(12): p. 6583-6592. 
21. Calhoun, W.J., et al., A common cold virus, rhinovirus 16, potentiates airway 
inflammation after segmental antigen bronchoprovocation in allergic subjects. The 
Journal of Clinical Investigation, 1994. 94(6): p. 2200-2208. 
22. Kua, K.P. and S.W.H. Lee, Systematic review of the safety and efficacy of 
palivizumab among infants and young children with cystic fibrosis. 
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy: p. 
n/a-n/a. 
23. Murray, C.S., A. Simpson, and A. Custovic, Allergens, Viruses, and Asthma 
Exacerbations. Proceedings of the American Thoracic Society, 2004. 1(2): p. 99-
104. 
24. Szabo, S.M., et al., Elevated risk of asthma after hospitalization for respiratory 
syncytial virus infection in infancy. Paediatric Respiratory Reviews, 2013. 13, 
Supplement 2(0): p. S9-S15. 
25. Newcomb, D.C., et al., IL-17A inhibits airway reactivity induced by respiratory 
syncytial virus infection during allergic airway inflammation. Thorax, 2013. 68(8): 
p. 717-723. 
26. Lotz, M., M. Moore, and R.S. Peebles, Jr., Respiratory Syncytial Virus and 
Reactive Airway Disease, in Challenges and Opportunities for Respiratory 
16 
 
Syncytial Virus Vaccines, L.J. Anderson and B.S. Graham, Editors. 2013, Springer 
Berlin Heidelberg. p. 105-118. 
27. Gupta, M.R., et al., <italic>Paramyxovirus</italic> Infection Regulates T Cell 
Responses by BDCA-1<sup>+</sup> and BDCA-3<sup>+</sup> Myeloid 
Dendritic Cells. PLoS ONE, 2014. 9(6): p. e99227. 
28. Collins PL, Crowe JEJ: Respiratory syncytial virus and metapneumovirus. 
2007:1601–1646. 
29. Akhras, N., J.B. Weinberg, and D. Newton, Human metapneumovirus and 
respiratory syncytial virus: subtle differences but comparable severity. Infectious 
Disease Reports, 2010. 2(2): p. e12. 
30. Fearns, R. and P.L. Collins, Role of the M2-1 transcription antitermination protein 
of respiratory syncytial virus in sequential transcription. J Virol, 1999. 73(7): p. 
5852-64. 
31. San-Juan-Vergara, H., et al., Cholesterol-Rich Microdomains as Docking 
Platforms for Respiratory Syncytial Virus in Normal Human Bronchial Epithelial 
Cells. Journal of Virology, 2012. 86(3): p. 1832-1843. 
32. Griffiths, C., S.J. Drews, and D.J. Marchant, Respiratory Syncytial Virus: Infection, 
Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev, 
2017. 30(1): p. 277-319. 
33. McCurdy, L.H. and B.S. Graham, Role of Plasma Membrane Lipid Microdomains 
in Respiratory Syncytial Virus Filament Formation. Journal of Virology, 2003. 77(3): 
p. 1747-1756. 
34. Marr, N. and S.E. Turvey, Role of human TLR4 in respiratory syncytial virus-
induced NF-kappaB activation, viral entry and replication. Innate Immun, 2012. 
18(6): p. 856-65. 
35. Fearns, R. and P.L. Collins, Model for polymerase access to the overlapped L gene 
of respiratory syncytial virus. J Virol, 1999. 73(1): p. 388-97. 
36. Tremaglio, C.Z., et al., Respiratory Syncytial Virus Polymerase Can Initiate 
Transcription from Position 3 of the Leader Promoter. Journal of Virology, 2013. 
87(6): p. 3196-3207. 
37. Zheng, J., et al., Respiratory Syncytial Virus Nonstructural Proteins Upregulate 
SOCS1 and SOCS3 in the Different Manner from Endogenous IFN Signaling. 
Journal of Immunology Research, 2015. 2015: p. 738547. 
17 
 
38. Boyapalle, S., et al., Respiratory Syncytial Virus NS1 Protein Colocalizes with 
Mitochondrial Antiviral Signaling Protein MAVS following Infection. PLOS ONE, 
2012. 7(2): p. e29386. 
39. Zhang, W., et al., Inhibition of respiratory syncytial virus infection with intranasal 
siRNA nanoparticles targeting the viral NS1 gene. Nat Med, 2005. 11(1): p. 56-62. 
40. Dupuy, L.C., et al., Casein Kinase 2-Mediated Phosphorylation of Respiratory 
Syncytial Virus Phosphoprotein P Is Essential for the Transcription Elongation 
Activity of the Viral Polymerase; Phosphorylation by Casein Kinase 1 Occurs 
Mainly at Ser(215) and Is without Effect. Journal of Virology, 1999. 73(10): p. 8384-
8392. 
41. Lu, B., et al., The Major Phosphorylation Sites of the Respiratory Syncytial Virus 
Phosphoprotein Are Dispensable for Virus Replication In Vitro. Journal of Virology, 
2002. 76(21): p. 10776-10784. 
42. Forster, A., et al., Dimerization of matrix protein is required for budding of 
respiratory syncytial virus. J Virol, 2015. 89(8): p. 4624-35. 
43. Russell, R.F., et al., Partial Attenuation of Respiratory Syncytial Virus with a 
Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-
1beta Responses. J Virol, 2015. 89(17): p. 8974-81. 
44. Meng, J., et al., Respiratory Syncytial Virus Attachment Glycoprotein Contribution 
to Infection Depends on the Specific Fusion Protein. Journal of Virology, 2016. 
90(1): p. 245-253. 
45. McLellan, J.S., W.C. Ray, and M.E. Peeples, Structure and Function of RSV 
Surface Glycoproteins. Current topics in microbiology and immunology, 2013. 372: 
p. 83-104. 
46. Collins, P.L., Y.T. Huang, and G.W. Wertz, Nucleotide sequence of the gene 
encoding the fusion (F) glycoprotein of human respiratory syncytial virus. 
Proceedings of the National Academy of Sciences of the United States of America, 
1984. 81(24): p. 7683-7687. 
47. Bermingham, A. and P.L. Collins, The M2-2 protein of human respiratory syncytial 
virus is a regulatory factor involved in the balance between RNA replication and 
transcription. Proc Natl Acad Sci U S A, 1999. 96(20): p. 11259-64. 
48. Noval, M.G., et al., Intrinsic Disorder to Order Transitions in the Scaffold 
Phosphoprotein P from the Respiratory Syncytial Virus RNA Polymerase Complex. 
Biochemistry, 2016. 55(10): p. 1441-1454. 
49. Collins, P.L. and B.S. Graham, Viral and Host Factors in Human Respiratory 
Syncytial Virus Pathogenesis. Journal of Virology, 2008. 82(5): p. 2040-2055. 
18 
 
50. Sande, C.J., et al., Group- and Genotype-Specific Neutralizing Antibody 
Responses Against Respiratory Syncytial Virus in Infants and Young Children With 
Severe Pneumonia. The Journal of Infectious Diseases, 2013. 207(3): p. 489-492. 
51. Sullender, W.M., Respiratory Syncytial Virus Genetic and Antigenic Diversity. 
Clinical Microbiology Reviews, 2000. 13(1): p. 1-15. 
52. Dudas, R.A. and R.A. Karron, Respiratory Syncytial Virus Vaccines. Clinical 
Microbiology Reviews, 1998. 11(3): p. 430-439. 
53. Dawson-Caswell, M. and H.L. Muncie, Jr., Respiratory syncytial virus infection in 
children. Am Fam Physician, 2011. 83(2): p. 141-6. 
54. Borchers, A.T., et al., Respiratory syncytial virus--a comprehensive review. Clin 
Rev Allergy Immunol, 2013. 45(3): p. 331-79. 
55. Papadopoulos, N.G., et al., Does respiratory syncytial virus subtype influences the 
severity of acute bronchiolitis in hospitalized infants? Respiratory Medicine, 2004. 
98(9): p. 879-882. 
56. Segovia, J., et al., TLR2/MyD88/NF-κB Pathway, Reactive Oxygen Species, 
Potassium Efflux Activates NLRP3/ASC Inflammasome during Respiratory 
Syncytial Virus Infection. PLoS ONE, 2012. 7(1): p. e29695. 
57. Takeuchi, O. and S. Akira, Innate immunity to virus infection. Immunological 
Reviews, 2009. 227(1): p. 75-86. 
58. Seth, R.B., et al., Identification and Characterization of MAVS, a Mitochondrial 
Antiviral Signaling Protein that Activates NF-κB and IRF3. Cell, 2005. 122(5): p. 
669-682. 
59. Demoor, T., et al., IPS-1 Signaling Has a Nonredundant Role in Mediating Antiviral 
Responses and the Clearance of Respiratory Syncytial Virus. The Journal of 
Immunology, 2012. 189(12): p. 5942-5953. 
60. Ivashkiv, L.B. and L.T. Donlin, Regulation of type I interferon responses. Nat Rev 
Immunol, 2014. 14(1): p. 36-49. 
61. Fensterl, V. and G.C. Sen, Interferons and viral infections. BioFactors, 2009. 35(1): 
p. 14-20. 
62. Mohapatra, S.S. and S. Boyapalle, Epidemiologic, Experimental, and Clinical Links 
between Respiratory Syncytial Virus Infection and Asthma. Clinical Microbiology 
Reviews, 2008. 21(3): p. 495-504. 
63. Spann, K.M., K.C. Tran, and P.L. Collins, Effects of Nonstructural Proteins NS1 
and NS2 of Human Respiratory Syncytial Virus on Interferon Regulatory Factor 3, 
19 
 
NF-κB, and Proinflammatory Cytokines. Journal of Virology, 2005. 79(9): p. 5353-
5362. 
64. Ling, Z., K.C. Tran, and M.N. Teng, Human Respiratory Syncytial Virus 
Nonstructural Protein NS2 Antagonizes the Activation of Beta Interferon 
Transcription by Interacting with RIG-I. Journal of Virology, 2009. 83(8): p. 3734-
3742. 
65. Olson, M.R. and S.M. Varga, Pulmonary immunity and immunopathology: lessons 
from respiratory syncytial virus. Expert Review of Vaccines, 2008. 7(8): p. 1239-
1255. 
66. Mukherjee, S. and N.W. Lukacs, Innate immune responses to respiratory syncytial 
virus infection. Curr Top Microbiol Immunol, 2013. 372: p. 139-54. 
67. Iwasaki, A. and R. Medzhitov, Control of adaptive immunity by the innate immune 
system. Nat Immunol, 2015. 16(4): p. 343-353. 
68. Domachowske, J.B. and H.F. Rosenberg, Respiratory Syncytial Virus Infection: 
Immune Response, Immunopathogenesis, and Treatment. Clinical Microbiology 
Reviews, 1999. 12(2): p. 298-309. 
69. Walsh, E. and A.R. Falsey, Humoral and Mucosal Immunity in Protection from 
Natural Respiratory Syncytial Virus Infection in Adults. The Journal of Infectious 
Diseases, 2004. 190(2): p. 373-378. 
70. Beem, M., R. Egerer, and J. Anderson, RESPIRATORY SYNCYTIAL VIRUS 
NEUTRALIZING ANTIBODIES IN PERSONS RESIDING IN CHICAGO, ILLINOIS. 
Pediatrics, 1964. 34: p. 761-70. 
71. Gellin, B., J.F. Modlin, and J.J.E. Crowe, Influence of Maternal Antibodies on 
Neonatal Immunization against Respiratory Viruses. Clinical Infectious Diseases, 
2001. 33(10): p. 1720-1727. 
72. Kruijsen, D., et al., Intranasal Administration of Antibody-Bound Respiratory 
Syncytial Virus Particles Efficiently Primes Virus-Specific Immune Responses in 
Mice. Journal of Virology, 2013. 87(13): p. 7550-7557. 
73. McIntosh, K., et al., The Immunologic Response to Infection with Respiratory 
Syncytial Virus in Infants. The Journal of Infectious Diseases, 1978. 138(1): p. 24-
32. 
74. Piedimonte, G. and M.K. Perez, Respiratory Syncytial Virus Infection and 
Bronchiolitis. Pediatrics in Review, 2014. 35(12): p. 519-530. 
20 
 
75. Willis, R.C., D.A. Carson, and J.E. Seegmiller, Adenosine kinase initiates the major 
route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A, 
1978. 75(7): p. 3042-4. 
76. Dixit, N.M. and A.S. Perelson, The metabolism, pharmacokinetics and 
mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life 
Sci, 2006. 63(7-8): p. 832-42. 
77. Aljabr, W., et al., Investigating the Influence of Ribavirin on Human Respiratory 
Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome 
Sequencing Approach. Journal of Virology, 2016. 90(10): p. 4876-4888. 
78. Beaird, O.E., et al., Current practices for treatment of respiratory syncytial virus 
and other non-influenza respiratory viruses in high-risk patient populations: a 
survey of institutions in the Midwestern Respiratory Virus Collaborative. Transplant 
Infectious Disease, 2016. 18(2): p. 210-215. 
79. Lavoie, P.M., et al., Outcomes of respiratory syncytial virus immunoprophylaxis in 
infants using an abbreviated dosing regimen of palivizumab. JAMA Pediatrics, 
2016. 170(2): p. 174-176. 
80. Geskey, J.M., N.J. Thomas, and G.L. Brummel, Palivizumab: a review of its use in 
the protection of high risk infants against respiratory syncytial virus (RSV). 
Biologics : Targets & Therapy, 2007. 1(1): p. 33-43. 
81. Chu, H.Y. and J.A. Englund, Respiratory Syncytial Virus Disease: Prevention and 
Treatment, in Challenges and Opportunities for Respiratory Syncytial Virus 
Vaccines, L.J. Anderson and B.S. Graham, Editors. 2013, Springer Berlin 
Heidelberg: Berlin, Heidelberg. p. 235-258. 
82. Hurwitz, J.L., Respiratory syncytial virus vaccine development. Expert Review of 
Vaccines, 2011. 10(10): p. 1415-1433. 
83. Openshaw, P.J., F.J. Culley, and W. Olszewska, Immunopathogenesis of vaccine-
enhanced RSV disease. Vaccine, 2001. 20 Suppl 1: p. S27-31. 
84. Waris, M.E., et al., Respiratory synctial virus infection in BALB/c mice previously 
immunized with formalin-inactivated virus induces enhanced pulmonary 
inflammatory response with a predominant Th2-like cytokine pattern. J Virol, 1996. 
70(5): p. 2852-60. 
85. Openshaw, P.J.M., et al., Protective and Harmful Immunity to RSV Infection. Annu 
Rev Immunol, 2017. 35: p. 501-532. 
86. Mejias, A., et al., Anti-respiratory syncytial virus (RSV) neutralizing antibody 
decreases lung inflammation, airway obstruction, and airway hyperresponsiveness 
in a murine RSV model. Antimicrob Agents Chemother, 2004. 48(5): p. 1811-22. 
 21 
 
 
 
 
 
CHAPTER 2 
GENERAL METHODS  
 
This section presents the general molecular biology techniques used during the 
course of the study. Two different approaches will be presented, in vivo and in vitro 
models of RSV infection; both are broadly used in the field to study RSV infection and its 
effect on the immune response and the pathology of disease.  
 
 
2.1      Mice 
Osteopontin-deficient knockout mice (OPN KO) (strain B6.Cg-Spp1tm1Blh/J) and 
wild type (WT) C57BL/6 were purchased from Jackson Laboratory. All animal work was 
approved by and performed in accordance with the policies of the University of South 
Florida Institutional Animal Use and Care Committee. Mice were acclimated for 7 days 
prior to the start of experiments. Mice were provided with standard rodent chow and water 
ad libitum. 
 
 
2.2      Cell Culture 
Human epithelial type 2, HEp-2, (CCL 23; American Type Culture Collection, 
Rockville, MD) and human embryonic kidney 293 cells, HEK-293, (ATCC CRL-1573) 
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were maintained in Dulbecco´s modified Eagle´s medium (DMEM, HyClone) 
supplemented with 5% fetal bovine serum (FBS, HyClone) and 1% penicillin-streptomycin 
(GIBCO). Cells were incubated at 37°C in a humidified incubator with 5% CO2/95%.  
 
 
2.3      Virus Purification, Infection and Plaque Assay 
Three different sources of RSV were used: rgRSV-A2 which expresses green 
fluorescent protein, the mucogenic rA2-L19F (RSV-L19F) recombinant variant of the A2 
strain with the fusion protein replaced with that of the line 19 RSV, and a version of the 
line 19 that expresses a red fluorescent protein (RSV-KL19F). The virus was propagated 
by infecting 60% confluent HEp-2 cells with a multiplicity of infection (MOI) of 0.1 plaque 
forming units (pfu) per cell for two hours at 37°C with gentle rocking every 15 minutes, 
after which the medium was replaced by fresh DMEM containing 5% FBS. Cells and 
media were collected when 70-80% of the cells showed cytopathological effects. RSV 
was pelleted through a layer of 30% glycerol (0.22 μm-filtered) in 0.1 M MgSO4 and 50 
mM HEPES, pH 7.5. The viral particles were pelleted by centrifuging at 11,600 rpm in an 
SW28 rotor for 3 h at 4°C. Supernatants were carefully aspirated without disturbing the 
viral pellets and the viral pellets were resuspended in pre-cooled, 0.22 μm-filtered 50 mM 
HEPES, pH 7.5, 0.1 M MgSO4, 150 mM NaCl. The resuspended pellet was aliquotted 
and stored at −80°C until use. UV-inactivation of RSV was performed by irradiating 
aliquots of virus with 1200 mJ of UV for 20 mins using a Stratalinker.  
For all the experiments, a monolayer of HEp-2 or HEK-293 cells at 80% confluence 
was infected with 0.1, 1 or 10 MOI (as indicated in the figure legends). Cells were 
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incubated with the viral inoculum in Opti-MEM containing 2% FBS (Life Technologies) for 
2 hours at 37°C. After this, the infectious medium was replaced by fresh DMEM with 5% 
FBS. At 24, 48 or 72 hours post infection (hpi) the cell supernatants and pellets were 
collected for viral plaque assay, RNA or protein analysis. 
WT or OPN KO mice were intranasally infected with 1 x 106 plaque forming units 
(pfu)/mouse of RSV-L19F in a BSL2, HEPA-filtered, ventilated hood. Mice were 
euthanized 1, 3 or 5 days post-infection (dpi). Lungs were collected for RNA or protein 
extraction. 
To determine the viral titers, HEp-2 cells were seeded in 24 well plates to 80% 
confluence and infected in duplicates with serial dilutions of cell supernatants during 2 
hours at 37°C. Infectious media was removed and cells were overlaid with 1 ml of 0.8% 
methylcellulose in DMEM supplemented with 5% FBS. 5 dpi, the cell monolayers were 
fixed overnight with 1 ml of 80% cold methanol. Next day, cells were rinsed with 
phosphate-buffered saline (PBS, Hyclone) and incubated with primary monoclonal 
antibody against RSV fusion protein (AbD Serotec). Plaques were visualized using an 
anti-mouse IgG horseradish peroxidase antibody (HRP)(Sigma) and developed with 4 CN 
peroxidase substrate (KPL); the dark purple spots were counted and each spot 
represented one plaque-forming unit (PFU). 
 
 
2.4      Quantitative RT-PCR 
Total RNA was isolated from cells using TRIzol (Life Technologies). Samples were 
treated with recombinant DNase I (Life Technologies) to remove any contaminating DNA. 
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1 μg of RNA was reverse transcribed using Maxima First Strand cDNA Synthesis Kit for 
RT-qPCR (Thermo Fisher Scientific) as described in manufacturer’s instructions. 
Quantitative real-time PCR (qPCR) was performed on the BioRad CFX384™ Real-time 
PCR Detection system using DyNamo Color Flash SYBR master mix (Thermo Fisher 
Scientific). The sequences of all primers used in this study are as follows (forward and 
reverse): RSV-N, 5’- CAT CTA GCA AAT ACA CCA TCC A-3′ and 5′-TTC TGC ACA TCA 
TAA TTA GGA GTA TCA A-3′; human IL-1β (PrimeTime® -qPCR primers-IDT), 5’- GAA 
CAA GTC ATC CTC ATT GCC-3’ and 5’-CAG CCA ATC TTC ATT GCT CAA G-3’; human 
OPN, 5’-TGG CCG AGG TGA TAG TGT G-3’ and 5’- CGG GGA TGG CCT TGT ATG-3’; 
human IFN-β, 5’-CAA CTT GCT TGG ATT CCT ACA AAG-3’ and 5’- TGC CAC AGG 
AGC TTC TGA CA-3’ . All samples were run in four replicates and the data were analyzed 
using normalized gene expression (ΔΔCt). Expression of all genes was normalized to 
control hypoxanthine-guanine phosphoribosyltransferase (HPRT): mouse HPRT, 5′-GCT 
GAC CTG CTG GAT TAC ATT AA-3′ and 5′-TGA TCA TTA CAG TAG CTC TTC AGT 
CTG A-3′; human HPRT, 5’- AGG AAA GCA AAG TCT GCA TTG TT-3’ and 5’- GGC TTT 
GTA TTT TGC TTT TCC A-3’. 
 
 
2.5     Western Immunoassay 
Cells were plated in 6-well culture plates the day before treatment/infection and 
harvested in lysis buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.0 and 
a protease inhibitor cocktail (Thermo Fisher Scientific). After removal of cellular debris by 
centrifugation, total protein concentration was measured at 660nm using protein assay 
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reagent (Thermo Fisher Scientific) and 25 μg of total protein were separated in a precast 
12% mini-PROTEAN TGX gel (Bio-Rad) and transferred to a nitrocellulose membrane 
(Bio-Rad). The membrane was incubated with a rabbit polyclonal antibody to human OPN 
(Abcam, ab181440) and a mouse monoclonal antibody to β-actin (Sigma). Proteins were 
detected by incubating with a secondary anti-mouse IgG-HRP and/or anti-rabbit IgG-
HRP, followed by the ECL reagent kit (Pierce). Images were captured using a ChemiDoc 
XRS+ imaging system (Bio-Rad). 
 
 
2.6      Immunofluorescence Microscopy  
HEp-2 cells were plated in 8-well chamber slides the day before infection. Cells 
were mock infected or infected with 1 MOI of RSV strain rA2-L19F. Cells were fixed with 
cold 4% paraformaldehyde 24 or 48 hpi and stained with a goat polyclonal antibody 
against RSV (Millipore, ab1128) and a rabbit polyclonal antibody to OPN (ABCAM), 
followed by indirect immunofluorescence using secondary anti-goat IgG Alexa Fluor-555- 
and anti-rabbit IgG Alexa Fluor-488-conjugated antibodies. Slides were mounted with 4′, 
6-diamidino-2-phenylindole (DAPI) containing anti-fade mounting media (Southern 
Biotech). A minimum of 10 images at 200X magnification were collected per slide with a 
DP72 digital camera on a BX51 Olympus fluorescence microscope on the appropriate 
fluorescence emission filter channels.   
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2.7     Enzyme-Linked Immunosorbent Assay (ELISA) in Lung Homogenates                                 
Snap frozen lungs were homogenized in cold lysis buffer containing 10 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1% NP-40, 10% Glycerol, 5 mM EDTA and a protease inhibitor 
cocktail. Tissue debris was pelleted by centrifugation at 4°C for 10 min at 300×g and 
protein concentration in the supernatants was measured at 660 nm with protein assay 
reagent (Thermo Fisher Scientific). Mouse osteopontin ELISA kit (RayBiotech) and 
mouse IL1-β ELISA kit (BioLegend) were used per manufacturer’s instructions.  
 
 
2.8      Flow Cytometry Assay for CD44 and RSV Infected Cells 
HEp2 or HEK-293 cells were seeded on 6-well plates at an appropriate cell density 
to reach 70 to 80% confluence. On the day of the experiment, each set of cell cultures 
was infected with RSV-KL19F for 2 hours. 24 hpi, cells were washed with PBS, detached 
with accutase (Life Technologies) and stained with DAPI to determine cell viability, FITC 
mouse anti-human CD44 antibody (BD Bioscience) or isotype control antibody. The 
percentage of cells expressing GFP (CD44 +) or RFP (RSV +) in each cell culture was 
determined by flow cytometry (BD FACSCanto II). Data was analyzed using BD FACS 
diva software. 
 
 
2.9      Recombinant IL-1β and OPN Treatment 
HEK-293 cells were infected with 1 MOI of rA2-L19F as described previously. 
Afterwards, the infectious media was replaced by fresh DMEM 5% FBS containing 
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different concentrations (0 - 1 and 10 ng/ml) of human rIL-1β (PeproTech). Similarly, HEK-
293 were treated four hours before infection with different concentrations (0 - 1 – 10 - 50 
- 100 and 200 ng/ml) of human rOPN (PeproTech) diluted in fresh DMEM 5% FBS. Cells 
were infected with rA2-L19F at 1 MOI, and two hours after infection the media were 
replaced by fresh DMEM 5% FBS containing rOPN. Protein and supernatants were 
collected for viral titering and western immunoassay. 
 
 
2.10   Caspase I Inhibitor (Ac-YVAD-CHO) Treatment  
HEp2 cells were treated with 10 μM of caspase I inhibitor (Sigma-Aldrich) or 
DMSO (vehicle control)  two hours preceding the infection. Afterwards, cells were 
infected with 1 MOI of RSV-L19F, and two hours later the infectious media was 
replaced by fresh media containing 10 μM  caspase I inhibitor or DMSO. Protein and 
RNA were isolated 24 hpi. 
 
 
2.11   CD44 Receptor-Neutralization and RSV Infection 
HEp-2 cells were seeded at 24-well plate the day before infection. On the 
infection day, cells were pre-treated at room temperature during 20 minutes with 10 μg 
broad spectrum rat-anti human CD44 antibody (clone A020) or normal rat IgG (control) 
(Millipore). After the pre-treatment, cells were infected with RSV-KL19F for two hours at 
37°C and infectious media was replaced with fresh growth media. After 24 hours, the 
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percentage of RSV positive cells was determined by flow cytometry (BD FACS Canto 
II). Data was analyzed using BD FACS diva software. 
 
 
2.12    Statistical Analysis 
 All the experiments were performed in triplicate and repeated at least twice. 
Statistical significance for each experiment was determined using Analysis of variance 
(ANOVA), p<0.05. Calculations were performed and graphs produced using Prism 6.0 
software (Graphpad Software, San Diego, CA, USA). Graphs of results show the mean 
and error bars depict the standard error of the mean, +/- SEM. 
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CHAPTER 3  
OPN EXPRESSION DURING RSV INFECTION IS REGULATED BY IL-1β 
 
3.1     Introduction  
As described in chapter 1, Respiratory Syncytial Virus (RSV) induces the 
expression of cytokines and chemokines in the cells that it infects. This intensifies the 
inflammatory process and contributes to progression of the RSV infection from a mild 
upper respiratory infection to  a severe lower respiratory infection that could lead to death 
when uncontrolled [1]. Understanding the diversity of cytokine function during infection 
can be a complicated process not only because different cell types secrete cytokines at 
different times during the infection, but also because the function of cytokines can vary 
depending on whether they act in an autocrine, paracrine or endocrine manner, thus 
contributing to their functional pleitrophy [2, 3].  
At present the mechanisms that contribute to severe RSV infection and viral 
pathogenesis remain unclear. Our lab has aimed to elucidate factors associated with RSV 
disease progression. Among those factors, Osteopontin (OPN) and Interleukin-1 beta (IL-
1ȕ) were associated with progression of RSV disease [4]. This chapter aims to elucidate 
the role of IL-1ȕ during RSV infection and how it plays a major role in amplifying the 
inflammatory response by regulating OPN expression and the progression of the 
infection. 
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3.1.1   Inflammasome Activation 
The innate immune response involves recognition of Pathogen Associated 
Molecular Patterns (PAMPs) and Damage Associated Molecular Patterns (DAMPs) by 
numerous pattern recognition receptors (PRR). The activation of these receptors leads to 
inflammation that aims to fight the infection or control harmful effects of chemicals on the 
cell [5]. The inflammasome pathway is a component of the innate immune response that 
gets activated upon pathogen recognition and signals of danger to the cells; the final 
products of inflammasome activation are Interleukin-1 beta (IL-1ȕ) and Interleukin-18 (IL-
18), which are known to amplify the inflammatory response and also modulate cell death 
[5, 6]. Five different receptors have been associated with inflammasome activation: 
nucleotide-binding oligomerization domain (NOD), leucine-rich repeat (LRR)-containing 
protein, NLR family members (NLRP1, NLRP3 and NLRC4), the proteins absent in 
melanoma 2 (AIM2) and pyrin [7]. Out of those, NLRP3, also known as NALP3, is the 
most well defined inflammasome pathway [8].  
Generation of IL-1ȕ requires assembly of the multi-protein inflammasome 
complex. There are two signals required for effective inflammasome activation. i) The 
priming signal ensures enough expression of the IL-1ȕ precursor (pro-IL-1ȕ) and an 
inflammasome receptor, such as NLRP3. The first signal is controlled by recognition of 
the pathogenic insult through PRR, which leads to activation of NF-κB and subsequent 
expression of pro-IL-1ȕ and genes related to the inflammasome complex [9]. The 
canonical inflammasome complex NLRP3 is composed of the NLRP3 sensor, the adaptor 
protein (ASC) and pro-caspase 1 [9, 10]. ii) The second signal involves activation of 
NLRP3 complex that leads to the processing of pro-caspase 1 to its active form, caspase-
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1. This step is critical since caspase-1 is required for the proteolytic cleavage of the 
inactive cytoplasmic precursors pro-IL-1ȕ [11]. The proposed mechanisms of caspase-1 
activation include pore formation and potassium efflux, lysosomal rupture that leads to 
release of cathepsin B, and the generation of mitochondrial reactive oxygen species 
(ROS) [10, 12, 13]. Briefly, after a pathogen is recognized by PRR and the levels of pro-
IL-1ȕ and NLRPγ are elevated, the monomers of NLRP3 undergo oligorimerization and 
the pyrin domain (PYD) of ASC protein allows their interaction [14]. Subsequently, the 
complex NLRP3-ASC allows the recruitment of pro-caspase-1 to the complex through a 
Caspase Recruitment Domain (CARD); hence pro-caspase-1 gets cleaved and 
generates an enzymatically active heterodimer of 20 kDa (p20) and 10 kDa (p10) subunits 
[14, 15]. The activation of caspase-1 leads to further processing of pro-IL-1ȕ and pro-IL-
18 that results in maturation and secretion of IL-1ȕ and IL-18 [15-18]. 
The genetic material (RNA or DNA) of several viral infections is recognized by PRR 
within the cells, which in turn activates the inflammasome pathway and contributes to the 
antiviral response [19]. NLRP3 activation is seen in influenza virus, Encephalomyocarditis 
Virus (EMCV), hepatitis C virus, Respiratory Syncytial Virus (RSV), Sendai Virus, and 
Dengue Virus infections, among others [19-23]. Among these, influenza virus infection is 
known to induce a robust IL-1ȕ expression via activation and recruitment of NLRPγ, ASC 
and caspase-1 [24, 25]. The activation of the first signal during influenza infection is 
granted by the recognition of the viral RNA by TLR-7; following TLR-7 activation the 
influenza M2 protein induces proton flux which activates the second signal that leads to 
inflammasome complex assembly and activation [24, 26, 27]. Similarly, RSV infection 
induces IL-1ȕ expression via activation of TLR-2 and TLR-4 that leads to pro-IL-1ȕ and 
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NLRP3 expression (first signal), and a potassium and ROS efflux that triggers 
inflammasome assembly (second signal) [28, 29].  
 
3.1.2   Inflammasome Regulation    
Inflammasome activation is essential to clear pathogens and damaged cells. After 
it has carried out its function inflammasome activity is typically downregulated since  
exaggerated inflammasome activation is associated with multiple diseases where 
uncontrolled inflammation disrupts the host balance and causes harm to the cells and 
tissues [30].  
IL-1ȕ is a strong pro-inflammatory cytokine that exerts its biological function by 
binding to its receptor, IL-1 receptor type I (IL-1R1). This binding results in the activation 
of intracellular signaling pathways which result in initiation of a cascade of inflammatory 
mediators [31, 32]. In contrast, a naturally occurring antagonist protein, IL-1 receptor 
antagonist (IL-1Ra), is essential to maintain equilibrium during the inflammatory 
response. It binds to IL-1R1 with higher affinity than IL-1ȕ and inhibits the recruitment of 
accessory proteins required for activation of pro inflammatory pathways [33]. Of note, the 
interaction of IL-1ȕ and IL-1R1 has been associated to the pathophysiology of some forms 
of pulmonary inflammation and airway remodeling (Fig. 2) [33, 34].  
As mentioned, regulation of inflammasome activation is fundamental for the 
maintenance of homeostatic biological functions; after inflammasome activation has 
exerted its function and the harmful stimulus is no longer an issue for the cell, the 
expression of Interferon (IFN) may down-regulate NLRP3 activity. For instance, IFN-Ȗ 
induces the expression of inducible nitric oxide synthase (iNOS) which produces nitric 
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oxide (NO) that hinders NLRP3 activity, whereas type I-IFNs disrupt the expression of 
pro-IL-1ȕ and pro-IL-18 and inhibit their cleavage via generation of NO and enhanced 
secretion of IL-10 that decrease the expression of the pro-cytokine forms [35-38]. In 
addition, the activation of NLRP3 is also controlled by miR-223 that silences NLRP3 
mRNA expression and leads to decreased protein levels, thus decreasing the activation 
of the pathway [39, 40].  
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Figure 2. Activation and regulation of the Inflammasome Pathway. The recognition 
of Pathogen Associated Molecular Patterns (PAMPs) by several Pathogen Recognition 
Receptors (PRR) results in activation of the inflammasome pathway. Two signals are 
required: a priming signal that results in the stimulation of PRR which leads to expression 
of inflammasome components such as NLRP3, pro-Il-1ȕ and pro-IL-18 (first signal); and 
the activation signal that involves oligomerization of NLRP3 and recruitment of  the 
adaptor protein ASC and pro-caspase 1, thus leading to caspase-1 activation and the 
processing and secretion of the inflammatory cytokines, IL-1ȕ and IL-18, which allows the 
interaction of the soluble cytokine with its receptor IL-1R1 so it can exert its function 
(second signal). Regulatory mechanisms aim to maintain the balance of the inflammatory 
response; hence secretion of type I IFN and IFN-Ȗ results in down-regulation of NLRP3 
activity that leads to inhibition of the inflammasome pathway. In addition, IL-1Ra 
expression has higher affinity to the receptor and its binding to IL-1R1 blocks the 
biological function of IL-1ȕ. 
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3.1.3   IL-1ȕ Expression during Infections 
Although the exact role of IL-1ȕ during viral infection is not fully elucidated, recent 
studies reported a dual function of IL-1ȕ during influenza infection where infection of IL-
1R1 knockout mice led to diminished inflammation but also decreased survival. The 
previous findings were explained by impairment in the recruitment of neutrophils and 
failure to recruit and activate CD4+ and CD8+ T cells [31, 41, 42]. Additionally, another 
study showed that lung fibroblast cells infected with influenza virus exhibited a reduction 
of pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α when they were pre-treated 
with IL-1Ra [43]. In agreement, IL-1Ra treatment used in patients with active chronic 
bacterial infections such as Sreptococcus pneumoniae and Streptococcus aureus 
reduces inflammation without exacerbating the infection [32]. Consequently, a controlled 
expression of IL-1ȕ seems to be essential for a proper antimicrobial response; however, 
chronic production of IL-1ȕ is detrimental as it increases the production of CXCL1, MIP-
2 and matrix metalloproteases that are associated with chronic infections and tissue 
damage [34]. These findings demonstrate that persistent expression of IL-1ȕ and other 
cytokines, although necessary to control viral replication early during the infection, also 
correlate with increased replication of the virus and severity of the disease [44].  
To validate the role of IL-1ȕ as a regulator of viral replication, a recombinant murine 
leukemia virus strain expressing IL-1ȕ (FMLV-IL-1ȕ) was used to infect murine fibroblasts 
or BALB/c mice; in vivo and in vitro FMLV-IL-1ȕ infections caused increased 
permissiveness to the infection that resulted in higher viral replication as compared to 
their FMLV counterpart. Although the mechanism is not fully understood, the authors 
speculated that IL-1ȕ enhances the susceptibility of the cells to the infection and/or up-
36 
 
regulates viral transcription in the infected cells by inducing activation and proliferation of 
neighboring cells, which in turn increases their chance of infection [45]. 
Although IL-1ȕ expression mediates viral clearance early during the infection, late 
expression of this cytokine has been associated with increased lung pathology 
characterized by increase mucus production, edema, cellular infiltration and a “cytokine 
storm” due to the capacity of IL-1ȕ to orchestrate and amplify the inflammatory process 
that leads to severe infection [46]. Previous studies have shown that infection of NLRP3 
KO mice with influenza virus results in exacerbation of the disease and difficulty clearing 
the infection; the previous results showed that NLRP3 activation and an appropriate IL-
1ȕ expression is essential for the resolution of the infection and overall survival of 
influenza infected mice [47, 48]. Additionally, when compared to WT mice infected with 
NLRP3, KO mice exhibited decreased neutrophil and monocyte recruitment and reduced 
cytokine production which correlated with their impaired antiviral response and 
susceptibility to the infection [48].  
On the other hand, a proper control of the infection is accomplished when 
activation of NLRP3 is reduced later during the infection, proving that prolonged IL-1ȕ 
expression is tightly associated with persistent and severe infection [49, 50]. Likewise, 
our previous studies in a murine model that compared the progression of RSV infection 
in aged vs. young mice showed that aged mice express higher levels of IL-1ȕ and OPN 
prior to infection compared to their younger counterparts, and this pro-inflammatory state 
that comes with aging impairs the antiviral response once those mice are exposed to RSV 
infection [4, 51]. Current evidence has shown that RSV induced cytokines control the 
onset of the infection, pathogenesis and evolution of the disease by disrupting the balance 
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between elimination of the virus and inflammation; likewise, uncontrolled inflammation is 
the base of many diseases. Consequently, this chapter aims to elucidate the regulatory 
role of IL-1ȕ orchestrating the pro-inflammatory state during RSV infection by modulating 
the levels of OPN expression. We hypothesize that persistent IL-1ȕ expression causes 
increased OPN levels that in turn negatively regulate the antiviral response, which leads 
to increased RSV infection. 
 
 
3.2      Results 
3.2.1   RSV Infection Up-regulates IL-1ȕ and OPN mRNA Expression in Epithelial Cells 
 
Our previous study in a murine model of infection showed that higher basal levels 
of IL-1ȕ and OPN in aged mice are associated with impaired antiviral response that leads 
to increased susceptibility to RSV infection.  In vitro, to evaluate the correlation of IL-1ȕ 
and OPN expression with susceptibility to RSV infection, we examined RSV infection in 
commonly used and highly susceptible HEp-2 cells and HEK-293 cells. HEK-293 cells 
were selected because they express low levels of endogenous pro-caspase1, which is 
essential for IL-1ȕ expression; therefore, they constitute a good model to compare viral 
infection and OPN expression in the absence of IL-1ȕ [28].  We found a significant 
increase in expression (reported as fold expression compared to mock-infected cells) of 
RSV-N and IL-1ȕ transcripts β4, 48 and 7β hpi in RSV-L19F-infected HEp-2 cells 
compared to RSV-L19F-infected HEK-293 cells (Fig. 3A and B). We compared OPN 
expression levels obtained by qPCR performed on RNA extracted from HEp-2 and HEK-
293 cells infected with 1 MOI of RSV-L19F. In a similar pattern to that of IL-1ȕ, OPN 
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expression was significantly increased 48 hpi in RSV-L19F-infected HEp-2 cells. In 
contrast, HEK-293 cells showed decreased RSV infection, lack of IL-1ȕ expression, and 
delayed OPN mRNA expression that was up-regulated 72 hpi (Fig. 3C). These results 
suggest that increased RSV infection up-regulates both OPN and IL-1ȕ expression. Also, 
lack of IL-1ȕ expression in HEK-293 cells correlates with resistance to RSV infection and 
delays OPN expression. 
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3.2.2   RSV Infection-Induced IL-1β Regulates OPN Expression.  
While the regulation of OPN expression is not fully understood, it is known that the 
expression of OPN is regulated by different stimuli, depending on the cells and tissues 
where it is expressed [52-54]. To examine the role of IL-1ȕ in the induction of OPN 
expression and to confirm that the production of OPN is not intrinsically impaired in HEK-
293 cells, cells were infected with 1 MOI of RSV-L19F, then the infectious medium was 
replaced with growth medium containing 1 or 10 ng/ml of human rIL-1ȕ. Incubation of 
HEK-293 cells with human rIL-1ȕ lead to increased OPN expression β4 hours after 
treatment. In addition, the RSV-L19F-infected HEK-293 cells treated with rIL-1ȕ showed 
higher levels of OPN expression compared to uninfected cells treated only with rIL-1ȕ 
(Fig. 4A). While rIL-1ȕ increased the expression of OPN after mock or RSV-L19F 
infection, it also contributed to an increase in viral yield in RSV-infected cells (Fig. 4B).  
Since HEK-293 and HEp-2 cells are likely to have other genetic differences which 
may influence OPN expression or susceptibility to RSV infection, we treated HEp-2 cells 
with a caspase-1 inhibitor (Ac-YVAD-CHO) in order to mimic the reduced IL-1ȕ 
expression seen in HEK-293 and establish that IL-1ȕ is responsible for the observed 
differences in RSV infection and OPN expression between the two cell lines. Cells were 
treated with the inhibitor and subsequently infected with RSV-L19F (1 MOI). Our results 
showed that cells treated with caspase-I inhibitor showed decreased IL-1ȕ mRNA levels 
(Fig. 4C). RSV-N mRNA levels and OPN protein expression were significantly reduced in 
those cells treated with the inhibitor as compared to control group (Fig. 4D and E). These 
results demonstrate the regulatory effect of IL-1ȕ and OPN expression in the progression 
of RSV infection. 
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Figure 4. RSV induced IL-1 β regulates OPN expression during RSV infection. HEK-
293 cells were mock-infected or infected with 1 MOI of RSV-L19F. 2 hours after the 
infection cells were treated with increasing concentrations of human rIL-1ȕ (0, 1 or 10 
ng/ml). (A) Protein was harvested β4 hpi for western blots. β5μg of protein lysate was 
loaded in each lane. OPN is seen at 55 kDa and ȕ-actin (loading control) at 42 kDa. (B) 
Plaque viral titers were obtained from the supernatants collected 24 hpi. (C-E) HEp-2 cells 
were pre-treated two hours prior RSV-L19F infection with 10 μM of Ac-YVAD-CHO 
(caspase-I) inhibitor. Cells were infected with 1 MOI of RSV-L19F and infectious media 
was replaced with fresh media containing 10 μM of Ac-YVAD-CHO. RNA and protein 
were collected 24 hpi. (C and D) Expression levels of IL-1ȕ and RSV-N were determined 
by qPCR. Results are presented as fold-change in expression of IL-1ȕ or RSV-N mRNA 
normalized to the control (HPRT). (E) β5μg of protein lysate was loaded in each lane. 
OPN is seen at 55 kDa and ȕ-actin (loading control) at 42 kDa. qPCR data are 
represented as means ±SEM. Experiments were performed in triplicate. **** p < 0.0001.  
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3.2.3   rOPN increases RSV Titers in a Dose-Dependent Manner  
To better understand the effect of increased OPN expression on viral yield during 
RSV infection and to validate that OPN expression is sufficient for the increase in viral 
titer seen in HEK-293 cells after treatment with rIL-1β. We used varying concentrations of 
human rOPN (0 - 1 - 10 - 50 - 100 and 200 ng/ml) to pretreat HEK-293 cells four hours 
before infection with 0.1 MOI of RSV-L19F. After infection, the medium was replaced with 
fresh growth medium containing rOPN at the same concentrations. 24 hours after 
infection, there was a significant dose-dependent increase in viral titers in cells treated 
with rOPN, further confirming that OPN promotes RSV infection (Fig. 5A). Additionally, to 
establish which step of the infection is benefited from OPN treatment, an intermediate 
OPN concentration (100 ng/ml) known to increase RSV infection was selected to treat the 
cells at three different time points: 1) four hours before the infection, 2) during the 
infection, or 3) after the infection. Our results show a significant increase in viral titers of 
cells treated with human rOPN during or after the infection (Fig. 5B). As an additional test 
of rOPN effect during the infection, HEp-2 and HEK-293 cells were infected with 0.1 MOI 
of the clinical strain Line 19 that expresses a red fluorescent protein-RFP (RSV-KL19F) 
in the presence of rOPN. We evaluated the number of RSV infected cells using flow 
cytometry.  We found that treatment with rOPN significantly increased the percentage of 
infected HEp-2 and HEK-293 cells by 23% and 20% respectively (Fig. 5C). These findings 
suggest that OPN could facilitate the entry of the virus into the cells and increase cell 
permissiveness to RSV infection. 
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Figure 5.  Human rOPN increases RSV titers in a dose-dependent manner. HEK-293 
cells were treated with increasing concentrations of human recombinant OPN (rOPN) (0 
to 200 ng/ml) four hours before infection. Cells were infected with 0.1 MOI of RSV-L19F 
and infectious media was replaced with fresh media containing the appropriate 
concentration of rOPN. (A) Supernatants were collected 24 hpi and viral titers were 
determined by plaque assay. (B) HEK-293 cells were treated with 100 ng/ml at different 
time points: before, during or immediately after the infection. (B) Supernatants were 
collected 24 hpi and viral titers were determined by plaque assay. Result of a 
representative experiment is shown. * p < 0.05, ** p < 0.01, **** p < 0.0001. (C). Hep-2 or 
HEK-293 cells were infected with 0.1 MOI of RSV-KL19F or RSV-KL19F in the presence 
of 100 ng/ml of rOPN. After 24 hours, the infected HEp-2 or HEK-293 cells were gated 
for RFP-expression (RSV + cells). Result of a representative experiment is shown. 
Experiments were performed in triplicate. 
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3.3      Discussion  
A major finding of our study is that IL-1ȕ is involved in regulating OPN levels during 
RSV infection. Our results suggest that OPN plays an important role in RSV infection and 
propagation in vivo and in vitro, and IL-1ȕ amplifies the inflammatory response by 
inducing OPN expression, resulting in increased viral loads. Our results show that 
although RSV infection can induce significant OPN expression in the absence of IL-1ȕ, 
in the presence of IL-1ȕ it can enhance and accelerate the infection process.   
The induction of OPN is controlled by a variety of cytokines, growth factors and 
hormones [52, 55, 56]. A previous study showed that IL-1ȕ dramatically increased OPN 
expression during pulmonary fibrosis through the activation of ERK1/2 but not by JNK 
pathway [57, 58]. Likewise, IL-1ȕ is one of the factors released at sites of injury that 
contributes to enhanced OPN expression [59]. RSV infection induces a substantial 
increase of IL-1ȕ, a pro-inflammatory cytokine known to induce the expression of a 
plethora of downstream pro-inflammatory cytokines including OPN, thus resulting in 
magnification of the inflammatory process [28, 29, 60, 61]. We have explored the 
association between IL-1ȕ and OPN up-regulation during RSV infection and our data 
shows that OPN and IL-1ȕ expression leads to increased viral infection. We also show a 
delay in OPN mRNA expression levels in infected HEK-293 cells compared to HEp-2 
cells, suggesting that the impaired production of IL-1ȕ in HEK-293 cells partially 
contributes to the reduced expression of OPN in the infected HEK-293. The increased 
early OPN expression in HEK-293 cells treated with rIL-1ȕ proves that the production of 
OPN is not intrinsically impaired in HEK-293 cells but instead is dependent on IL-1ȕ 
signaling. The correlation between increased OPN protein levels and increased RSV viral 
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titers in HEK-293 cells treated with rIL-1ȕ further confirms the role of these two pro-
inflammatory cytokines in the regulation of RSV infection. Similarly, to rule out other 
differences between HEK-293 and HEp-2 cells, we inhibited caspase-I expression in 
HEp-2 cells and showed that this inhibition leads to a decrease in IL-1ȕ expression that 
also results in decreased OPN expression and decreased viral infection. 
We have consistently observed an increase in OPN expression in cells and mice 
infected with RSV. In order to evaluate the feedback effect of high OPN levels on RSV 
infection we treated HEK-293 with human rOPN during RSV infection. Our results showed 
that HEK-293 cells treated with human rOPN displayed a dose-dependent increase in 
viral titers, suggesting that OPN has a regulatory effect on RSV infection. Moreover, the 
results of studies on timing of OPN action show the prominent effect of OPN during the 
infection process itself. Cells treated with rOPN during and immediately after the infection 
yielded higher viral titers, while cells pre-treated with OPN before the infection did not 
show a significant difference in viral titers when compared to RSV infected cells without 
rOPN treatment. This suggests that OPN mediates increased entry and/or assembly of 
the virus leading to a significant increase in plaque viral titers. 
Further, cells treated with rOPN became infected with RSV at a significantly higher rate 
than untreated cells.  
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CHAPTER 4 
OPN EXPRESSION DURING RSV INFECTION  
 
4.1       Introduction  
 Osteopontin is a multifunctional secretory protein also known as secreted 
phosphoprotein 1 (SPP 1) and early T-lymphocyte activation-1 (Eta-1) [1]. Although it was 
first identified in osteoclasts and is highly expressed in bone, OPN is also secreted by a 
variety of cells and tissues including macrophages, smooth muscle cells, epithelial and 
endothelial cells [1-3]. OPN has anti- and pro-inflammatory activity depending on cell 
context; hence it has been associated with multiple physiological and pathological 
conditions.  
The duality of OPN function can be explained by the complexity of its structure, 
which has six translated exons that can undergo alternative splicing and multiple post-
translational modifications. This results in a number of OPN forms with different functions: 
OPN-a, the full length protein; OPN-b, which lacks exon 5; and OPN-c, which lacks exon 
4 (Fig. 6) [1, 4]. Although the function of this alternative splicing has not been 
characterized in many diseases, it has been reported that excision of exon 5 is essential 
to maintain OPN physiological functions; hence OPN-b expression is associated with anti-
apoptotic activity. Lack of exon 4 in OPN-c results in increased solubility that makes OPN 
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more accessible to its integrin receptors, thus enhancing signaling that leads to cell 
migration and cancer metastasis [5-8]. The full-length OPN is composed of 300 amino 
acids and is expressed as a 33 to 75 KDa protein depending on the specific post-
translational modifications [9-11].  
The induction of OPN is controlled by a variety of cytokines, growth factors, and 
hormones [12]. Examples of growth factors involved with OPN regulation are transforming 
growth factor β, epidermal growth factor and fibroblast growth factor [9, 12]. Additionally, 
the glucocorticosteroids dexamethasone, progesterone and other hormones can regulate 
its expression [9]. OPN expression is also regulated by mediators of acute inflammation 
such as IL-1β, tumor necrosis factor α (TNF-α), IL-2, IL-3, NO and IFN-β among others 
[13-16]. Up-regulation of OPN has been shown after activation of phosphoinositide 3-
kinase pathways (PI3K), extracellular signal-regulated kinase (ERK), and c-Jun N-
terminal kinase (JNK) [1]. 
OPN contains a highly conserved Arg-Gly-Asp (RGD) integrin binding domain that 
allows its interaction with αvβ1, αvβ3, αvβ5, αvβ6, α8β1, α5β1 integrins and the CD44 
hyaluronic acid receptor [8, 11]. The association of OPN with these receptors also 
explains the diversity of OPN function and its association with multiple signaling pathways 
[11]. 
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Figure 6. Splice variants of Osteopontin. The OPN gene has six translated exons 
which produce the full length protein (OPN-a 33kDa) when all are transcribed. Deletion 
of exons 5 and 4 leads to OPN-b and OPN-c expression respectively. Exon 2 contains 
the signal peptide required for OPN secretion, whereas exon 6 has a tripeptide Arg-Gly-
Asp (RGD) domain that is recognized by integrins and CD44 receptor. 
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4.1.1   Role of OPN Expression and Regulation of the Immune Response  
OPN modulates the immune response by facilitating neutrophil and macrophage 
migration to the site of injury. It also promotes dendritic cell maturation and migration to 
the lymph nodes where they can present antigens to naïve T cells, thus serving as a 
bridge between the innate and the cell-mediated immune response [9]. Likewise, OPN 
has been associated with Th17-related pathologies like human T-lymphotropic virus 1 
infection, acute coronary syndrome, arthritis, and Trypanosoma cruzi infection, where 
endogenous levels of OPN seem to positively regulate the Th17 cytokine response that 
promotes inflammation [17-19]. 
Recent studies have shown that OPN expression was up-regulated in serum and 
bronchial tissue samples from mild to moderate asthmatics, and increased levels of OPN 
correlated with the severity of the disease [20-22]. Similarly, OPN levels are up-regulated 
in serum and tissue samples from chronic rhinosinusitis and allergic patients [16, 20]. 
Xanthau et al. further explored the mechanism by which OPN is involved in asthma and 
allergic diseases by showing that during primary sensitization, OPN blocks the migration 
of plasmacytoid dendritic cells to draining lymph nodes, resulting in an increased 
inflammatory response and exacerbated allergic symptoms. However, during secondary 
antigenic challenge OPN up-regulation resulted in inhibition of conventional dendritic cells 
recruitment, which consequently reduced the Th2 response and associated  airway 
hyperresponsiveness [23]; thus, the role of OPN in respiratory disease remains 
inconclusive. 
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OPN function has been the focus of research in several microbial infections; it has 
been credited with antimicrobial functions against Klebsiella pneumoniae and 
Mycobacterium tuberculosis [24, 25]. OPN deficiency leads to severe endodontic 
infections [26]. Some researchers found a significant increase in OPN protein in the lungs 
of WT mice after influenza infection; however, there was no viral load or lung pathology 
difference between infected WT and OPN KO mice. A second study showed that OPN 
KO mice exhibited severe pathology and decreased survival after influenza infection [27, 
28]. Although the authors did not explain the difference in the results, the discrepancies 
could be attributed to the difference in the inoculum used to infect the mice. Similar to 
influenza, RSV induces a substantial increase of IL-1β, which is a critical cytokine able to 
amplify the pro-inflammatory response that follows infection [29, 30]. RSV infection 
induces the expression of several cytokines including IL-1β, IL-6 and chemokines such 
as IL-8 and TNF-α that contribute to inflammation and the pathology of the infection [31-
33]. However, whether the inflammation contributes to increased viral load and spread of 
infection is unclear.  
In an effort to dissect the molecular basis of severity of RSV infection, previously 
we conducted a microarray analysis and identified several genes that are influenced by 
aging and RSV infection. These studies led to identification of five up-regulated genes 
including osteopontin (OPN), which hitherto had not been studied in RSV infection [34]. 
Thus, the main goal of this chapter is to establish the effect of OPN during RSV infection; 
our hypothesis is that OPN increases cell permissiveness to RSV infection and 
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accelerates the infection process, which leads to increased viral titers in epithelial cells 
expressing OPN. 
 
 
4.2      Results 
4.2.1   RSV Replication is not required for Increased OPN Expression 
To assess baseline levels of OPN and subsequent changes in expression upon 
RSV infection, HEp2 cells were infected with RSV-L19F at 1 MOI (1 PFU/cell) and the 
levels of OPN were confirmed by immunostaining of mock- or RSV-L19F-infected HEp2 
cells; results showed elevated OPN expression in the virus-infected cells compared to 
mock-infected cells. There were comparatively fewer OPN-positive cells in the mock-
infected than RSV-L19F-infected cells 48 hpi (Fig. 7A).  
To examine the role of RSV replication during OPN induction and to determine 
whether RSV proteins alone could initiate OPN induction, HEp2 cells were infected with 
increasing doses (0.1, 1 and 10 MOI) of UV-inactivated RSV-L19F, native RSV-L19F or 
mock treatment. To evaluate the productivity of the infection, supernatants were used for 
RSV titration by plaque assay. As expected, the number of PFU increased in a dose-
dependent manner from 0.1 to 10 MOI in RSV-L19F infected cells. There was no 
productive infection in the UV-attenuated virus (Fig. 7B). Protein was isolated 48 hpi for 
Western blot analyses. OPN expression was proportional to the MOI dose of the RSV—
higher in 10 MOI-infected cells compared to 0.1 or 1 MOI-infected cells (Fig. 7C). 
Furthermore, OPN expression was higher in RSV-L19F-infected cells than in cells 
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infected with the UV inactivated virus. However, at 10 MOI of UV-inactivated RSV there 
was some up-regulation in the expression of OPN, suggesting that RSV proteins or 
nucleic acids present in the inactivated form of RSV continued to contribute to OPN 
induction and expression. 
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Figure 7. RSV infection induces OPN expression in a dose dependent manner. 
HEp2 cells were mock-infected or infected with RSV-L19F (1 MOI). (A) Images of Hep2 
cells stained with polyclonal antibody against RSV and OPN at 48 hpi.  Representative 
images of RSV-positive (red) cells, OPN positives (green) cells, and DAPI (blue) nuclear 
staining at 200X magnification. (B) RSV titer by plaque assay of supernatants for 
increasing doses (0.1, 1 and 10 MOI) of UV-inactivated and native RSV-L19F at 48 hpi. 
(C) OPN protein (55 kDa) expression in HEp2 cells at 48 hpi after mock, RSV and UV-
inactivated RSV treatment in the indicated doses analyzed by western blots. β-actin 
(loading control) at 42 kDa was probed as the loading control.  
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4.2.2   CD44 Expression Mediates RSV Infection in Epithelial Cells 
CD44 is known to be a receptor for OPN. To evaluate the expression of CD44 in 
mock or RSV infected cells, HEp-2 and HEK-293 cells were infected with 0.5 MOI of RSV-
KL19F. 24 hours after infection, cells were stained with a FITC-CD44 antibody and gated 
for CD44 or isotype control (green) and RSV (red) expression. We found higher cell 
surface expression of CD44 in the HEp-2 cell line (96.7%) than in HEK-293 (73.7%). We 
also found a significant difference in the number of RSV positive cells, confirming that 
HEp-2 is more permissive to RSV infection (Fig. 8). These results suggest that the earlier 
OPN expression in HEp-2 cells and the concomitant CD44 expression could be key 
mediators for OPN signaling during RSV infection that potentiates the infection of HEp-2 
cells. 
To test whether CD44 expression is required for RSV infection, the CD44 receptor 
was neutralized with a broad-spectrum rat anti-human CD44 antibody. Briefly, HEp-2 cells 
were pre-incubated for 20 minutes at room temperature and then infected with RSV-
KL19F (0.5 MOI) for two hours, after which the infectious media was replaced with fresh 
growth media. 24 hpi we assessed the number of RSV positive cells (RFP +) by flow 
cytometry. We found ~52.4% of the cells were RSV positive in the cells pre-treated with 
CD44 antibody compared to 70.5% RSV positive cells in the control group. Our results 
showed a decrease in RSV positive cells following treatment with anti-CD44 antibody 
prior to infection compared to normal rat IgG control (Fig. 9). Together, these data suggest 
that CD44 facilitates the RSV infection process. 
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Figure 8. CD44 expression mediates RSV infection. HEp-2 or HEK-293 cells 
were infected with 0.5 MOI of RSV-KL19F (red). After 24 h, the cells were stained with 
FITC mouse anti-human CD44 antibody (green) and also gated for RSV expression (red). 
(Top panel) Flow cytometry analysis of HEp-2 cells infected with RSV-KL19F. (Bottom 
panel) Flow cytometry analysis of HEK-293 cells infected with RSV-KL19F. Result of a 
representative experiment is shown. Experiments were performed in triplicate. 
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Figure 9. Neutralization of CD44 receptor reduces the number of RSV 
positive cells. Hep-2 cells were pre-treated with 10 μg of broad spectrum rat-anti human 
CD44 antibody (clone A020) or normal rat IgG (control). After the pre-treatment, cells 
were infected with RSV-KL19F (0.5 MOI) and infectious media was replaced with fresh 
growth media. After 24 hours, the percentage of RSV positive cells was determined by 
flow cytometry. Result of a representative experiment is shown. Experiments were 
performed in triplicate. 
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4.3     Discussion 
To our knowledge our lab is the first one to determine the importance of OPN for 
RSV infection in vitro and in vivo. Our data has shown the association between increased 
OPN levels and increased RSV replication [34].  
To establish the mechanism for OPN up-regulation and also to verify that OPN 
was expressed in human epithelial cells infected with RSV, we infected HEp-2 cells with 
RSV-L19F and verified through immunostaining and qPCR that RSV triggers OPN 
expression. Also, we found up-regulation of OPN after infection with UV irradiated-RSV-
L19F, while the UV inactivated virus led to lower expression of OPN protein levels 
compared to replicating RSV-L19F. Therefore, loading more antigenic proteins and 
nucleic acids initiates OPN induction, suggesting replication is not absolutely required for 
the expression of OPN.  
Also, we found that HEp-2 highly expressing the OPN receptor CD44 showed a 
higher percent of infected cells compared to HEK-293 cells whose expression of CD44 is 
lower. Although the basis of OPN regulation of RSV entry and/or assembly remains 
unclear, one possibility is that OPN modulates the fusion process itself, thus aiding virus 
entry. This idea is supported by the observation that the OPN receptor (CD44) co-
localizes with RSV F protein and results in viral filament formation and syncytia formation 
which benefit the infectious process [35]. Additionally, the decrease we observed in RSV-
positive cells after CD44 receptor neutralization evidenced that any manipulation of 
components of the lipid rafts which disrupts CD44 signaling could negatively affect the 
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infection process; thus our results suggest that the interaction of proteins at the lipid rafts, 
like OPN and its receptor (CD44), could favor the infection process.    
In support of our findings, OPN has been associated with lung disease progression 
[36, 37]. During lung infection, OPN expression was associated with impairment of the 
innate immune response and decreased antibacterial function of effector antimicrobial 
peptides [38], which resulted in increased susceptibility to infection by Streptococcus 
pneumoniae and Pseudomonas aeruginosa [38]. Another study showed lower S. 
pneumonia bacteria loads in the lungs of OPN KO mice as compared to WT infected mice, 
suggesting that OPN enhanced the primary infection of the respiratory tract by increasing 
the viability of the bacteria [39].  
Overall increased OPN levels during bacterial infections have been reported and 
associated to increase susceptibility to infections; however, the role of OPN during viral 
infection remains inconclusive. During viral lung infection, higher levels of OPN in the 
serum of patients infected with influenza correlated with increased severity of the infection 
and pulmonary edema which can be explained by increased pro-inflammatory cytokine 
production [40]. Additionally, OPN up-regulation has been proposed as a key cytokine 
modulating chronic hepatitis C infection (HCV); and increased OPN expression was found 
in cells that are more susceptible to HCV infection while neutralization of OPN expression 
correlates with decreased viral replication [36]. Similarly, Dengue infection is another 
example of OPN up-regulation during exacerbation of a viral infection [41].  
With regard to lung pathology, OPN is not only associated with infectious diseases; 
several studies also associated OPN expression and lung cancer progression [42-44]. 
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OPN has been postulated to increase metastasis and anti-apoptotic activity of the cancer 
cells, which results in increased metastatic phenotype in lung cancer [44, 45].  
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CHAPTER 5 
SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION AND OSTEOPONTIN 
EXPRESSION 
 
5.1     Introduction  
Respiratory syncytial virus (RSV) is one of the first pathogens encountered by 
infant immune systems. The infection is regularly characterized by cold like symptoms. 
However, complications arising from RSV infection can cause acute lower respiratory 
infection (ALRI) leading to bronchiolitis and pneumonia in up to 30% of the infected infants 
[1]. In the United States alone, RSV causes up to 90,000 hospitalizations and 1.7 million 
visits to the doctor office  [2]. RSV infection represents a healthcare burden as treatment 
of its related disease costs up to $400 million each year [2, 3], which is not surprising if 
we consider that by the age of two years old all infants are expected to suffer from the 
infection at least once [4]. 
RSV is known to cause re-infection throughout life because the immune response 
to the infection does not lead to long lasting immunity. Therefore, assessing the risk 
factors associated with severe RSV infection is important to protect individuals that are 
more susceptible to complications [5, 6]. Among these risk factors are pre-term infants, 
children with malignancies, congenital diseases, acquired or congenital immune 
deficiency, cystic fibrosis, Down syndrome, and other severe respiratory diseases [7].   
RSV is a major producer of inflammation of the small airways, also known as 
bronchiolitis. This is one of the leading causes of infant hospitalization and admission to 
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the intensive care unit (ICU) [8-11]. A recent study evaluated the association between 
bronchiolitis and viral infections in young children (≤ 5 years). The authors found that RSV 
was detected by RT-PCR in 73% of the samples whereas Rhinovirus (RV) was found in 
30% of them and the combination RSV and RV in 41% of all the samples [12].  
Severe RSV infection has been recognized as a risk factor for the development of 
pneumonia in the elderly (> 65 years) [13]. A retrospective study done in adults in the 
United States evidenced that RSV is associated with higher numbers of severe infections, 
associated hospitalizations and increased mortality than Influenza infection, particularly 
in older adults that were immunocompromised [14].  
RSV infection is associated with a set of pathological changes of the respiratory 
epithelium. These include necrosis of the tissue, goblet cell hypermetaplasia, severe 
inflammation and a plug of mucus that leads to airway obstruction and edema, which is a 
hallmark of severe respiratory disease [15-17]. Both the viral load and the host immune 
response control the pathological changes following RSV infection [18]. In vivo, several 
studies have aimed to elucidate the pulmonary changes associated to RSV infection. 
Recent studies have used murine models to mimic RSV disease. The authors used two 
different viral strains, A2 and line 19 [15, 19]. The A2 strain is a common strain of human 
RSV available from the American Type Culture Collection (ATCC).The line 19 strain is 
derived from a clinical isolate and is associated with severe RSV disease and mucus 
production [20, 21]. In comparison, BALB/c mice infected with line 19 shown significant 
increase in gob5, MUC5AC and IL-13 protein expression that correlate with mucus 
production and airway obstruction compared to native A2-infected mice [20, 21]. In 
addition, the mucogenic line 19 is associated with increased viral loads which can explain 
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the increase in mucus production since more viral factors are being expressed and are 
thought to contribute to the inflammatory process [15].  
In humans, RSV infects ciliated airway epithelial cells leading to necrosis of 
epithelial cells and tissue damage that results in accumulation of cell debris, 
macrophages, neutrophils and mucus production that leads to airway obstruction [22]. In 
addition, bronchoalveolar lavage (BAL) secretions associated with severe RSV infection 
are rich in neutrophils, pro-inflammatory cytokines and chemokines such as Interleukin-6 
(IL-6), IL-10, IL-5, IL-4, IL-13, tumor necrosis factor-α (TNFα), and MCP-1 among others 
[23, 24]. Therefore, a robust inflammatory response is associated with the clinical 
outcome and disease severity in humans. However, other host genetic factors and 
specific features associated with the virus itself also have an influence in the severity of 
the disease [25]. 
The current understanding of RSV disease in humans is incomplete. Therefore, 
modeling RSV disease in vivo remains a good approach to increase our knowledge of 
viral pathogenesis and progression of the disease. RSV infection has been studied in 
chimpanzees, cattle, cotton rats, guinea pig, sheep and mice [24, 26]. Ideally, a good 
animal model of RSV infection should mimic pathological characteristics of the human 
infection. Infection by the line 19 antigenic strain of the virus has been associated with 
similar effects to the ones seen in human infection including airway hyperreactivity, 
increased mucus production and similar cytokine production [27]. 
Although RSV was discovered more than five decades ago and despite the 
ongoing research and clinical trials, there is no treatment or vaccine available. 
Immunoprophylaxis remains the key to prevent severe RSV infection in high-risk 
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population [28, 29]. OPN is up-regulated in other inflammatory lung diseases, such as 
asthma, and RSV has been implicated in asthma exacerbation. Therefore, we reasoned 
that OPN might be involved in regulating susceptibility to severe RSV infection. To test 
this hypothesis we investigated the role of OPN in RSV infection.  
In this chapter we compare human epithelial cells and mice infected with RSV-
L19F, a strain that produces severe infection associated with increased viral loads, to 
rgRSV-A2 which induces mild infection and moderated viral loads. This allows us to 
establish if OPN expression is correlated with increased spread of the virus between cells 
and increased cell permissiveness to RSV infection.  
 
 
5.2      Results 
5.2.1   OPN Expression is a Marker of High RSV Loads in HEp-2 Cells (in vitro) 
To investigate the role of OPN in determining the severity of RSV infection, HEp-2 
cells were infected with rgRSV-A2 or RSV-L19F. The latter is known to induce severe 
RSV infection and higher viral loads in a mouse model [15]. In vitro, infection with rgRSV-
A2 and RSV-L19F resulted in similar plaque viral titers and RSV-N gene expression at 24 
hpi (Fig. 10A and B). However, at 48 hpi RSV-L19F-infected cells had a significantly 
increased number of viral plaques and a similar increase in RSV-N mRNA expression 
when compared to cells infected with rgRSV-A2 (Fig. 10A and B). Following the same 
pattern, we found no significant difference in the gene expression of IL-1β at 24 hpi with 
the two RSV strains, but we noted a significant up-regulation of IL-1β mRNA expression 
48 hpi with RSV-L19F compared to rgRSV-A2 (Fig. 10C). Remarkably, IFN-β mRNA 
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levels were significantly elevated 24 hpi in rgRSV-A2-infected cells compared to those 
infected with RSV-L19F. This may in part account for the difference in viral titers and 
RSV-N transcripts observed in cells infected with the different viral strains (Fig. 10D).  
Western blot analysis revealed an increase in OPN protein expression at 24 hpi that 
remained high at 48 hpi in RSV-L19F-infected cells. Cells infected with rgRSV-A2 showed 
less OPN protein expression at 24 hpi and the expression started to return to baseline 
levels by 48 hpi (Fig. 10E).  
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Figure 10. OPN is a marker of high RSV loads in HEp-2 cells. HEp-2 cells were mock-
infected or infected with 1 MOI of RSV-L19F or rgRSV-A2. RNA, supernatants and protein 
were isolated 24 and 48 hpi. (A) Plaque titers were obtained from supernatants of HEp-2 
cells infected with RSV-L19F or rgRSV-A2. (B - D) Expression of RSV-N, IL-1β and IFN-
β were determined by qPCR. Results are presented as fold-change in expression of RSV-
N, IL-1β or IFN-β mRNA normalized to the control (HPRT). (E) Western blot analysis of 
OPN expression. 25μg of protein lysate was loaded in each lane. OPN is seen at 55 kDa 
and β-actin (loading control) at 42 kDa. Experiments were performed in triplicate. * p < 
0.05,  ** p < 0.01, **** p < 0.0001. 
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5.2.2   RSV Replication is diminished in Mice Lacking OPN (OPN KO). 
 
To determine the time points where IL-1β and OPN expression are induced and 
their effect during RSV infection, we infected OPN KO and WT mice intranasally with the 
mucogenic virus, RSV-L19F. Mice were euthanized 1, 3 and 5 dpi. As we reported before 
[21], RSV infection resolves much faster in OPN KO mice than WT. This was evidenced 
by a significant decrease in RSV-N transcripts at 5 dpi in the lungs of OPN KO mice as 
measured by qRT-PCR.  There were no significant differences in RSV-N amplification 1 
or 3 dpi, but the infection did not progress to 5 dpi in OPN KO mice as it did in WT mice 
(Fig. 11A). Secretion of IL-1β was also measured upon infection since it was suspected 
to play a role in controlling OPN expression during RSV infection. We found a significant 
increase in IL-1β expression 1 dpi in both OPN KO and WT mice infected with RSV-L19F, 
yet there was no significant difference between the two strains of mice at 1 dpi. 
Nonetheless, at 5 dpi RSV infected WT mice had increased levels of IL-1β while in the 
OPN KO mice IL-1β levels returned to baseline (Fig. 11B). The expression of OPN in 
RSV-L19F-infected WT mice was also determined and compared to mock-infected WT. 
OPN protein levels were measured by ELISA of lung homogenates. We observed a 
significant increase in OPN protein levels at 3 and 5 dpi in WT mice infected with L19F 
(Fig. 11C). As expected, the levels of OPN were below the detection limit in RSV-L19F or 
mock-infected OPN KO mice (Fig. 11C). 
 
5.2.3   OPN Expression is a Marker of high RSV Loads (in vivo) 
Furthermore, we infected WT mice in increased doses of RSV-L19F (1 or 3 x 106) 
and found a significant increase in OPN protein levels that correlated with the increased 
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viral concentration used to infect those mice (Fig. 12A). We also evaluated the effect of 
mild or severe RSV infection in vivo and how it influenced OPN expression.  WT mice 
were infected with mock, RSV-L19F or rgRSV-A2. Similar to the results found in vitro, WT 
mice infected with RSV-L19F exhibited higher OPN protein levels compared to those 
infected with rgRSV-A2 (Fig. 12B). These results suggest that increases in OPN 
expression levels are closely associated with RSV viral loads.  
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Figure 11. RSV replication is diminished in mice lacking OPN (OPN KO). C57BL/6 
and OPN KO mice were mock-infected or infected with 3 x 106 RSV-L19F. Lungs were 
collected 1, 3 and 5 dpi for protein and RNA extraction. (A) RSV-N mRNA expression 
levels were determined by qPCR and results represented as fold-change in expression 
of RSV-N mRNA normalized to the control (HPRT). (B and C) Levels of OPN and IL-1β 
in lung homogenates were determined by ELISA. BD: Below detection limits. Lung 
homogenates were obtained from individual mice and not pooled (n>4 per group). ** p < 
0.01, **** p < 0.0001. 
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Figure 12. OPN expression is a marker of high RSV loads in vivo. (A) C57BL/6 mice 
were mock-infected or infected with 1 or 3 x 106 RSV-L19F. (B) C57BL/6 mice were mock-
infected or infected with 3 x 106 RSV-L19F or rgRSV-A2. (A-B) Lungs were collected 3 
dpi for protein isolation and levels of OPN in lung homogenates were determined by 
ELISA. Lung homogenates were obtained from individual mice and not pooled (n>4 per 
group). * p < 0.05,  ** p < 0.01, **** p < 0.0001. 
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5.3     Discussion 
A comparative analysis of virus infection, IL-1β, OPN and IFN-β expression by two 
RSV strains (lab isolate rA2 versus the mucogenic strain RSV-L19F) showed that OPN 
expression was significantly higher in RSV-L19F compared to rA2. Also, our in vivo 
studies in a mouse model of RSV infection showed that IL-1β expression preceded OPN 
expression in WT mice after RSV infection. Importantly, we found a significant difference 
in infection at 5 dpi, where WT infected mice exhibited increases in RSV-N gene 
amplification compared to OPN KO mice. This data is consistent with a previous study 
done by our lab where we found decreased viral titers from lung homogenates and fewer 
RSV-positive lung cells in the OPN KO mice infected with RSV compared to WT mice 
[21]. Further, these results are consistent with reports of increased levels of OPN 
positively correlated with severity of lung inflammation [30-34]. OPN up-regulation in 
serum and tissue samples from chronic rhinosinusitis and allergic patients also correlated 
with severity of disease [30, 35, 36]. In agreement with these studies, a recent paper 
found a positive correlation between increased levels of OPN in human serum and 
disease severity in influenza patients [37]. Our in vitro findings suggest that IFN-β reduces 
the viral infection resulting in decreased IL-1 β and OPN expression and it is consistent 
with previous reports where RSV-A2 infection resulted in significantly higher expression 
of IFN-α than RSV-L19F in human epithelial cells and BALB/c mice [15, 38]. Additional 
studies have reported decreased OPN levels in serum samples from multiple sclerosis 
patients treated with IFN-β, supporting this INF-β dependent mechanism of OPN 
regulation [39-41]. Also, an inverse relationship between IFN-β and OPN expression 
reported in recent data indicates that the fusion protein of the virus could directly modulate 
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type I IFN expression and that the increase in viral loads after RSV-L19F infection lead 
to higher expression levels of viral non-structural proteins (NS1 and NS2). These are 
known to disrupt type I IFN response and therefore may act to increase OPN [15, 42-44]. 
Together, these pathophysiological differences between non-severe and severe RSV 
strains suggest that OPN could be used as a marker of severe RSV infection. 
Proper control of the inflammatory response is required not only for effective viral 
clearance but also for prevention of subsequent complications caused by imbalanced 
immune response and exaggerated inflammation during RSV infection [45]. It has been 
suggested that the severity of the disease caused by RSV is controlled not only by the 
replication of the virus but also by the host inflammatory response. Therefore, these two 
factors together could help us predict the severity of the disease and perhaps establish 
new treatments aiming to control infection and inflammation [46-48]. An accurate profiling 
of inflammatory mediators is a promising strategy to explore RSV physiopathology that 
could contribute to a better management of RSV disease. 
Taken together, our in vitro and in vivo data has shown a correlation between OPN 
protein expression levels and RSV viral loads. Cells and mice infected with RSV-L19F 
exhibit increased viral replication that results in a better propagation of the infection 
compared to infection with RSV-A2. Our results proved that increased levels of OPN 
protein are sufficient to increase viral loads, thus influencing the onset and severity of 
infection.  
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CHAPTER 6 
CONCLUSIONS 
 
To the best of our knowledge, our lab was the first to determine the importance of 
OPN during RSV infection; however, the mechanism underlying the role of OPN in RSV 
infection remained to be elucidated.  Herein, the results from a series of in vivo and in 
vitro experiments show the molecular mechanisms linking OPN expression with 
increased susceptibility to RSV infection. The salient findings of the present studies are 
as follows: i) RSV infection leads to increased IL-1β and OPN expression, ii) IL-1β is 
involved in the regulation of OPN levels during RSV infection, iii) increased OPN 
expression alone is sufficient to enhance RSV infection and contribute to viral spread, 
and iv) OPN is a predictive marker of viral loads both in vitro and in vivo.  
In chapter 1 we provided evidence that concomitant expression of IL-1β and OPN 
upon RSV infection increases susceptibility to RSV. We found a positive correlation 
between both high IL-1β and high OPN expression levels with increased RSV loads. In 
addition, we established that IL-1β is partially involved in the increase in OPN expression 
during RSV infection. Although OPN expression was not exclusively required for RSV 
infection, early expression of OPN during the infection is associated with a rapid increase 
in viral loads and spread of the infection among neighboring cells. 
In chapter 2 we have shown that RSV replication is not required for OPN 
expression. We found OPN expression is higher in cells infected with live virus compared 
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to those infected with UV-inactivated RSV. This finding suggests that RSV infection and 
replication is a major trigger of OPN expression, although in the absence of viral 
replication there remained some OPN expression. This suggests that stimulation of the 
innate immune response by viral genomic material and proteins can also activate OPN 
expression. While the mechanism of action of OPN during RSV infection is not fully clear, 
we found that neutralization of OPN receptor (CD44) prior to the infection correlates with 
a decrease in RSV positive cells. Our data suggest that the interaction between OPN and 
its receptor CD44 is a key step that facilitates RSV infection process, presumably by 
altering associated lipid rafts.  
In chapter 3 we compared (in vitro and in vivo) IL-1β and OPN expression in two 
RSV strains. RSV-L19F is known to induce higher viral loads than RSV-A2. Our results 
showed that increased levels of RSV-N transcript and viral titers positively correlated with 
OPN protein levels in cells and mice infected with RSV-L19F. These differences between 
the non-severe and severe RSV strains showed that OPN expression correlates with 
increased viral loads in lung homogenates from RSV-infected mice and supernatants 
from infected cells. This suggests that OPN could be used as a marker for severe infection 
or to evaluate the effect of treatments during infection. 
Together, the results of these studies have pointed to the role of OPN during RSV 
infection. The first cycle of RSV infection proceeds in an OPN-independent fashion, where 
the viral nucleic acid is recognized by PRR leading to IL-1β expression, and subsequently 
to OPN up-regulation. Therefore, the second replication cycle of the virus can be said to 
be OPN-dependent, wherein the interaction of OPN and its receptor (CD44) results in 
increased viral fusion to subsequent host cells that results in an increased number of 
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infected cells within the tissue and therefore increased overall viral progeny production 
(Fig. 13). 
The knowledge acquired from this research could be used in the future to develop 
new drug targets for treatment and/or prophylaxis of RSV infection since it may lead to 
development of pharmacological strategies that allow for regulation of IL-1β and OPN 
expression during infection. As addressed before, inflammation is required for successful 
viral clearance. However, an exaggerated immune response can be harmful not only 
because it can lead to tissue damage and exaggerated mucus production that leads to 
airway obstruction, but also because an improper immune response can be associated 
with increased viral loads and dissemination of the infection. Our study has laid the 
foundation for future prospective research designed to better understand the complex 
mechanism of severe RSV infection and better design effective treatments able to 
modulate infection and lead to a proper control of the inflammation.  
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Figure 13. Model for the role of OPN during RSV infection. (Left panel) OPN-
independent model. During RSV infection, the virus is recognized by the host cells 
through PRR (TLR-3, RIG-I, TLR-7); recognition of the virus leads to activation of the 
innate immune response which leads to release of anti-viral and pro-inflammatory 
cytokines like IFN-β and IL-1β. Expression of IL-1β leads to up-regulation of OPN 
whereas expression of IFN-β down-regulates OPN expression. (Right panel) OPN-
dependent model. Fusion of RSV is accelerated in the presence of OPN and its receptor 
(CD44), thus leading to an increased number of infected cells, which results in increased 
viral loads.    
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